



Published in final edited form as:

*J Med Chem.* 2013 December 12; 56(23): 9457–9470. doi:10.1021/jm400793v.

## Explorations of Substituted Urea Functionality for Discovery of New Activators of the Heme Regulated Inhibitor Kinase

Ting Chen<sup>†, \*\*</sup>, Khuloud Takroui<sup>†, \*\*</sup>, Sung Hee-Hwang<sup>#</sup>, Sandeep Rana<sup>##</sup>, Revital Yefidoff-Freedman<sup>†</sup>, Jose Halperin<sup>†</sup>, Amarnath Natarajan<sup>##</sup>, Christophe Morisseau<sup>#</sup>, Bruce Hammock<sup>#</sup>, Michael Chorev<sup>†</sup>, and Bertal H. Aktas<sup>†, \*</sup>

<sup>†</sup>Hematology Laboratory for Translational Research, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA

<sup>#</sup>Department of Entomology and University of California Davis Comprehensive Cancer Center, University of California, One Shields Avenue, Davis, California 95616

<sup>##</sup>Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha NE 68198

### Abstract

Heme-regulated inhibitor kinase (HRI), an eukaryotic translation initiation factor 2 alpha (eIF2 $\alpha$ ) kinase, plays critical roles in cell proliferation, differentiation, and adaptation to cytoplasmic stress. HRI is also a critical modifier of hemoglobin disorders such as  $\beta$ -thalassemia. We previously identified *N,N'*-diarylureas as potent activators of HRI suitable for studying biology of this important kinase. To expand the repertoire of chemotypes that activate HRI we screened a ~1,900 member *N,N'*-disubstituted urea library in the surrogate eIF2 $\alpha$  phosphorylation assay identifying *N*-aryl,*N'*-cyclohexylphenoxyurea as a promising scaffold. We validated hit compounds as *bona-fide* HRI activators in secondary assays and explored contributions of substitutions on the *N*-aryl and *N'*-cyclohexylphenoxy groups to their activity by studying focused libraries of complementing analogs. We tested these *N*-aryl,*N'*-cyclohexylphenoxyureas in the surrogate eIF2 $\alpha$  phosphorylation and cell proliferation assays, demonstrating significantly improved bioactivities and specificities. We consider these compounds to represent lead candidates for the development of potent and specific HRI activators.

### Keywords

SAR study; *N,N'*-disubstituted ureas; inhibition of translation initiation; ternary complex; phosphorylation of eIF2 $\alpha$

### Introduction

The eukaryotic translation initiation factor 2 (eIF2) forms ternary a complex with initiator methionine transfer RNA (Met-tRNA<sub>i</sub>) and GTP, which is critically required for recognition of translation start codon. Hydrolysis of GTP in the eIF2-GTP-Met-tRNA<sub>i</sub> ternary complex and release of inorganic phosphate, Pi, are coupled to start-codon recognition and initiation

\*To whom correspondence should be addressed. Phone: (617) 525-3142. Fax: (617) 582-6069. huseyin\_aktas@hms.harvard.edu.

\*\*These authors contributed equally.

“Supporting Information Available: The screened compound library showing compounds' effect on F/R ratio in the surrogate eIF2 $\alpha$  phosphorylation assay, activity of *N*-phenyl-*N'*-(4-((2,6-difluorobenzyl)oxy)cyclohexyl)ureas in the surrogate eIF2 $\alpha$  phosphorylation and cell proliferation assay, time response studies of selected compounds in the surrogate eIF2 $\alpha$  phosphorylation assay, and HRMS data of the synthesized compounds. This material is available free of charge via the internet at <http://pubs.acs.org>.”

of translation. The exchange of GDP in the eIF2·GDP binary complex for GTP is catalyzed by eIF2B, a guanine nucleotide exchange factor. This GDP-GTP exchange is the rate-limiting step for the formation of the ternary complex and initiation of a new round of translation. Phosphorylation of alpha subunit of eIF2 (eIF2 $\alpha$ ) on S51 by eIF2 $\alpha$  kinases-HRI, RNA-dependent-protein-kinase/protein kinase R (PKR), pancreatic eIF2 $\alpha$  kinase/PKR-like endoplasmic reticulum kinase (PERK), and general control non-derepressible-2 (GCN2)- is the major mechanism that regulates the GDP-GTP exchange. More specifically, S51 phosphorylation on eIF2 $\alpha$  concomitantly increases its affinity for eIF2B and inhibits eIF2B's guanine nucleotide exchange activity. Because the eIF2 is present in excess over eIF2B (low eIF2B/eIF2 stoichiometry), even partial phosphorylation of eIF2 $\alpha$  results in sequestration of eIF2B thereby reducing the amount of the eIF2·GTP·Met-tRNA<sub>i</sub> ternary complex, and inhibiting translation initiation<sup>1, 2</sup>.

Formation of the eIF2·GTP·Met-tRNA<sub>i</sub> ternary complex is tightly coupled to cell physiology and plays critical roles in normal- and patho-biology<sup>3-9</sup>. Proliferating cells synthesize proteins at much higher rate than quiescent cells of similar types. The lower rate of translation in quiescent cells is achieved in part by higher rate of eIF2 $\alpha$  phosphorylation compared to proliferating cells. Phosphorylation of eIF2 $\alpha$  is essential for coupling protein synthesis to heme availability in red blood cells progenitors, to the folding capacity of ER-Golgi network in the secretory cells, and to the nutrient and oxygen availability in almost all cells.

Consistent with its role in the normal-biology, deregulation of eIF2 $\alpha$  phosphorylation is implicated in the patho-biology of various human disorders. For example, inactivating mutations of PERK cause Wolcott-Rallison syndrome, a rare autosomal recessive disease characterized by neonatal/early-onset non-autoimmune insulin-requiring diabetes associated with skeletal dysplasia and growth retardation syndrome<sup>10, 11</sup>. Insufficiency of eIF2 $\alpha$  phosphorylation in red blood cells progenitors, i.e. those deficient in HRI, increases the severity of hemolytic disorders such as  $\beta$ -thalassemia<sup>12-14</sup>. Deregulation of eIF2 $\alpha$  phosphorylation has also been implicated in the pathogenesis of neurodegenerative disorders such as Alzheimer's disease and proliferative disorders such as cancer<sup>15, 16</sup>. Forced expression of eIF2 $\alpha$ -S51A, a non-phosphorylatable mutant, increases the amount of the ternary complex, renders the translation initiation unrestricted, and causes transformation of normal cells<sup>17, 18</sup>. Similarly, overexpression of MettRNA<sub>i</sub>, which increases the amount of the ternary complex, causes cellular transformation<sup>19</sup>. In contrast, induction of eIF2 $\alpha$  phosphorylation pharmacologically or by over-expressing eIF2 $\alpha$  kinases inhibits proliferation of cancer cells *in vitro* and tumor growth *in vivo*<sup>20-24</sup>.

These findings clearly indicate that small molecule activators of eIF2 $\alpha$  kinases, particularly of HRI, are important tools for studying the patho-biology of certain human disorders and/or may be deployed for their treatment. This task is highly dependent on discovery of HRI activators whose potency, specificity, and physico-chemical properties can be improved by structure-activity relationship (SAR) studies. Such hits should ideally be based on druggable molecular scaffolds suitable for facile synthesis. We previously reported discovery and preliminary SAR studies of *N,N'*-diarylureas as activators of HRI<sup>25, 26</sup>. *N,N'*-diaryl- as well as *N*-aryl,*N'*-alkyl-ureas, such as 12-(3-adamantane-1-ylureido)dodecanoic acid (AUDA), were reported to be potent inhibitors of soluble epoxide hydrolase (sEH)<sup>27, 28</sup>. We therefore advanced the hypothesis that *N,N'*-disubstituted urea analogs other than *N,N'*-diarylureas may also activate HRI and induce eIF2 $\alpha$  phosphorylation. If correct, this will allow greater structural versatility that will lend itself to the discovery and development of more potent and selective HRI activators.

Herein, we report screening of a ~1,900 member diversity *N,N'*-disubstituted urea library, originally developed to inhibit sEH<sup>29, 30</sup> and discovery of *N*-phenyl,*N'*-cyclohexylphenoxy compounds as activators of HRI. We evaluated selected hit compounds for induction of endogenous eIF2 $\alpha$  phosphorylation and expression of its downstream effector, CHOP protein and mRNA, and inhibition of the expression of oncogenic proteins. We further determined the dependence of the activity of these agents on HRI at the molecular and cellular level. We then undertook structure-activity relationship study of novel HRI activators as the first step in a hit-to-lead optimization process. To this end, we synthesized focused libraries of *N*-phenyl,*N'*-cyclohexylphenoxy ureas to assess structural latitude and improve their potency. These newly synthesized compounds were characterized for induction of eIF2 $\alpha$  phosphorylation in a surrogate cell-based reporter assay as well as inhibition of cell proliferation in sulforhodamine B (SRB) binding assay, which assessed the biological consequences of eIF2 $\alpha$  phosphorylation. Selected analogs were further evaluated for specificity in functional genetic studies.

## Results and discussion

### Chemistry

Substituted ureas of interest that were not commercially available and considered to be important for structure-activity relationship studies (**I-11o** and **I-12o**), or designed for the initial hit-to-lead optimization (**I-14-20** and **III-1-5**), were synthesized as described in Schemes 1 and 2. Reacting equimolar amounts of the appropriate cyclohexylamine and phenyl isocyanate yielded the anticipated *N*-phenyl,*N'*-cyclohexylaryl ureas in good yield. The substituted *trans*-(4-phenoxy)cyclohexylamines (**1-7**) were generated from *trans*-4-aminocyclohexanol and the appropriately substituted fluorobenzenes following previously reported procedures<sup>31</sup>. The urea incorporating the *cis*-1,4-disubstituted cyclohexyl moiety, **I-11o** was obtained by reacting methyl 2-isocyanatobenzoate with a small excess of *cis*-4-(4-fluorophenoxy)cyclohexylamine, **1b** in DCM/DMSO at room temperature (Scheme 1 B). The amine **1b** was synthesized from *trans*-4-aminocyclohexanol and 4-fluorophenol via Mitsunobu coupling reaction as described earlier<sup>34</sup>.


Modifications of position of the phenoxy substituent on the cyclohexyl ring of the ureas (**III-1-5**) were obtained by reacting the 3-(trifluoromethyl)phenyl isocyanate with the properly substituted cyclohexylamines (**8-10**), which were either commercially available or synthesized as described in Scheme 2. The substituted cyclohexylamines were obtained by the *O*-alkylation of *m*-aminocyclohexanol using 4-substituted fluorobenzenes, as in **8-9**, and the *trans*-4-Boc-aminocyclohexanol with alkyl halides followed by deprotection to obtain **10**, the free amine. Reaction of the free amines with 3-(trifluoromethyl)phenyl isocyanate produced ureas **III-1-5** as described in Scheme 2 and the Experimental Section.

Based on analytical reverse-phase high performance liquid chromatography (RP-HPLC) analysis the purity of all final *N*-aryl,*N'*-cyclohexylarylureas submitted to biological characterization and reported in here equaled or exceeded 95%. Some of the pure compounds comprise of racemic mixtures originating from the non-symmetrically disubstituted cyclohexyl moieties. Their structural identity and integrity was confirmed by HR- or LC-MS, <sup>1</sup>H-, <sup>13</sup>C-, and <sup>19</sup>F-NMR.

**Identification of *N*-phenyl,*N'*-cyclohexylarylureas**—We screened a diversity library of ~1900 urea compounds in the dual luciferase (DLR) surrogate eIF2 $\alpha$  phosphorylation (ternary complex) assay. This library was originally assembled and screened for inhibition of sEH by Hammock's group at UC-Davis. We developed surrogate dual-luciferase eIF2 $\alpha$  phosphorylation assay in order to identify compounds that activate HRI<sup>25, 32</sup>, taking advantage of the fact that activated HRI phosphorylates eIF2 $\alpha$  thereby reducing the amount

of the eIF2-GTP-Met-tRNA<sub>i</sub> ternary complex that inhibits translation of many mRNAs but paradoxically increases translation of some mRNAs that contain multiple upstream ORF (uORF) in their 5' untranslated regions (UTRs). In our assay, firefly (F) luciferase mRNA is fused to 5'UTR of activating transcription factor 4 (ATF-4) mRNA 5'UTR that has multiple uORFs while renilla (R) luciferase mRNA is fused to a 5'UTR lacking any uORFs. Compounds that reduce the amount of the ternary complex, such as those that activate HRI, would increase F luciferase while decreasing the R luciferase expression, resulting in an increased F/R luciferase ratio. We calculated the activity scores as the F/R ratios for every compound-treated wells and normalized these for F/R ratio in vehicle-treated (DMSO) wells that was arbitrarily set at 1 (F/R = 1).

We screened compound library at 33 $\mu$ M concentration in 384-well plate format. The activity of all tested compounds in the primary screening assay is shown in Table S1. Interestingly, there is no correlation ( $r^2 < 0.15$ ) between induction of eIF2 $\alpha$  phosphorylation and the previously reported inhibition of sEH by these compounds<sup>30</sup> suggesting distinct structure-activity relationship. Of interest in this library were the *N*-phenyl-*N'*-(4-(4-fluorophenoxy)cyclohexyl)urea (**I**) and *N*-phenyl-*N'*-(4-((2,6-difluorobenzyl)oxy)cyclohexyl)urea (**II**, see supporting information) scaffolds; they were re-evaluated by dose-response studies in the dual luciferase surrogate eIF2 $\alpha$  phosphorylation<sup>25</sup> and SRB cell proliferation<sup>33</sup> assays (Table 1, Figure 1, and Table S2). This re-testing served the dual purpose: confirming the results of the primary screen and establishing the pharmacologically required dose-response relationships. Importantly, screening the library we had few pairs of *cis*- and *trans*-isomers of the same compound for which we did not see significant difference in biological activity. The greater commercial availability of the *trans*-aminocyclohexanols was the predominant reason we decided to focus our studies on the *trans*-configuration.




### Structural-activity relationship

In the *N*-phenyl-*N'*-(4-phenoxy)cyclohexylureas **I**, the nature and position of the substitution on the *N*-phenyl moiety have significant impact on the compound's activity in both the surrogate eIF2 $\alpha$  phosphorylation and cell proliferation assays (Table 1 and Figure 1). The unsubstituted *N*-phenyl derivative, **I-13** is devoid of measurable activity in both assays. All the mono-substituted *N*-phenyl compounds show substituent position-dependent activity that varies with the nature of the substituent. In general, there is a very good correlation between the mechanistic surrogate eIF2 $\alpha$  phosphorylation and the cell proliferation assays. The most potent compounds are those substituted with electron withdrawing groups *p*-OCF<sub>3</sub> (**I-6p**, F/R<sub>@30 $\mu$ M</sub> = 15.32; IC<sub>50</sub>=2.7  $\mu$ M), *m*- and *p*-CF<sub>3</sub> (**I-5m** and **I-5p**, F/R<sub>@30 $\mu$ M</sub> = 11.84 and 13.99; IC<sub>50</sub>=2.6 and 2.8  $\mu$ M, respectively) and *p*- and *m*-NO<sub>2</sub> (**I-9p** and **I-9m**, F/R<sub>@30 $\mu$ M</sub> = 9.0 and 7.47; IC<sub>50</sub>=2.3 and 6.7  $\mu$ M, respectively), *m*- and *p*-CO<sub>2</sub>Me (**I-11m** and **I-11p**, F/R<sub>@30 $\mu$ M</sub> = 6.83 and 3.97; IC<sub>50</sub>=9.7 and 11.6  $\mu$ M, respectively), and *p*-CO<sub>2</sub>H (**I-12p**, F/R<sub>@30 $\mu$ M</sub> = 3.49). The *m*-OCF<sub>3</sub> analog was generated with purity short of the required 95% and was therefore not tested. The halogen substituted ureas **I-1**-to-**I-4** (12 analogs, R<sub>1</sub>=halogen) comprises a second sub-set of compounds active in both assays. In this sub-set, substitution in either *ortho*- or *meta*-position result in active compounds with the *meta* being

the most active for every halide (e.g. **I-1m** and **I-1o**, *m*- and *o*-F,  $F/R_{@30\mu M} = 6.54$  and  $2.10$ ;  $IC_{50} = 8.3$  and  $17.5 \mu M$ , respectively, and **I-4m** and **I-4o**, *m*- and *o*-I,  $F/R_{@30\mu M} = 7.63$  and  $3.25$ ;  $IC_{50} = 5.2$  and  $>20 \mu M$ , respectively). In the entire series presented in Table 1, the *ortho* position is the least favorable one. Electron donating substituents (**I-7** CH<sub>3</sub>-, **I-8** CH<sub>3</sub>O-, and **I-10** CH<sub>3</sub>S-) in the *meta*-position yields the most active ureas (**I-7m**, **I-8m**, and **I-10m**, *m*-CH<sub>3</sub>, *m*-OCH<sub>3</sub>, and *m*-SCH<sub>3</sub>,  $F/R_{@30\mu M} = 4.73$ ,  $3.81$ , and  $6.67$ ;  $IC_{50} = 14.4$ ,  $14$ , and  $11.1 \mu M$ , respectively). On the other hand, for electron withdrawing substituents the most active ones are the *para*-substituted urea (*p*-CF<sub>3</sub>/**I-5p**, *p*-CF<sub>3</sub>O/**I-6p**, *p*-NO<sub>2</sub>/**I-9p**, and *p*-CO<sub>2</sub>H/**I-12p**). The trifluoromethoxy group that has been referred to as a super-<sup>34</sup> or a pseudo-halogen<sup>35</sup> and is best represented as a partially polarized function carrying partial positive and negative charges on the oxygen and fluorines, respectively<sup>36</sup>. Comparison of **I-1p**, **I-5p**, and **I-6p** show the great advantage of *p*-trifluoromethoxy and *p*-trifluoromethyl over the *p*-fluoro substituent in terms of potency both in the cell proliferation and surrogate eIF2 $\alpha$  phosphorylation assay, latter expressed by the ~15 fold higher  $E_{max}$ . Therefore, combination of the highly polarized C-F bonds, the low polarizability of the most electronegative fluorine atom, and the high lipophilicity of the trifluoromethyl and trifluoromethoxy groups may be responsible for this interesting SAR. Evidently, **I-9p** that is substituted by highly polar *p*-NO<sub>2</sub> group characterized by a strong negative inductive effect is less potent in the mechanistic surrogate eIF2 $\alpha$  phosphorylation assay than the *p*-CF<sub>3</sub> substituted **I-5p** and the *p*-CF<sub>3</sub>O substituted **I-6p** (cf.  $F/R_{@30} = 9.00$  vs.  $13.99$  and  $15.32$ , respectively). Apparently, high lipophilicity parameters ( $\pi_x$ ) of the substituent combined with a strong negative inductive effect contribute to high potency ( $\pi_x = -0.02$ ,  $0.14$ ,  $0.56$ ,  $0.88$ , and  $1.04$  for X = OCH<sub>3</sub>, F, CH<sub>3</sub>, CF<sub>3</sub>, and OCF<sub>3</sub>, respectively<sup>35</sup>). There is no correlation between the biological potency and cLogP for either the cell proliferation or the ternary complex assays.

Importantly, a parallel SAR study carried out on *N*-phenyl-*N'*-(4-((2,6-difluorobenzyl)oxy)cyclohexyl)ureas **II** (27 analogs, Table S2), which differ from ureas in series **I** only by replacing the 4-fluorophenoxy with the (2,6-difluorobenzyl)oxy, demonstrated to be devoid of activity in both the surrogate eIF2 $\alpha$  phosphorylation and cell proliferation assays. We were quite encouraged by this observation suggesting a remarkable level of scaffold-target specificity.



### Activities in secondary mechanistic assays

To confirm that the *N*-phenyl,*N'*-(4-phenoxy)cyclohexylureas activate HRI and thereby induce phosphorylation of eIF2 $\alpha$ , we selected representative compounds from Table 1, (*N*-phenyl,*N'*-(4-phenoxy)cyclohexylureas (**I**), and tested them in secondary mechanistic assays, namely endogenous eIF2 $\alpha$  phosphorylation and expression of the transcription factor C/EBP homologous (CHOP) protein and mRNA. The surrogate eIF2 $\alpha$  phosphorylation assay utilized for screening is a reporter gene assay that relates to a downstream event, namely up-regulating translation of a reporter fused to the 5'UTR of ATF-4 mRNA in response to the reduced abundance of the ternary complex. Phosphorylation of endogenous eIF2 $\alpha$ , which inhibits recycling of the eIF2-GDP to eIF2-GTP is the direct target of HRI and upstream regulator of the ternary complex abundance while the expression of CHOP is a



downstream effector of ternary complex abundance. The *N*-phenyl,*N'*-(4-phenoxy)cyclohexylureas (**I**) selected for these secondary mechanistic studies cover a range of potencies in the surrogate eIF2 $\alpha$  phosphorylation and cell proliferation assays. We first determined their effect on the phosphorylation of endogenous eIF2 $\alpha$  in CRL-2813 cells by the Western blot analysis in which expression of the total (T-eIF2 $\alpha$ ) and the phosphorylated eIF2 $\alpha$  (P-eIF2 $\alpha$ ) was determined using specific antibodies (Figure 2). We also studied by Western blot analysis expression of CHOP protein and by real-time PCR expression of CHOP mRNA. Similarly, we studied the expression of cyclin D1 protein and mRNA, an oncogenic protein whose expression is reduced in response to eIF2 $\alpha$  phosphorylation (Figure 3). As anticipated, all compounds caused phosphorylation of endogenous eIF2 $\alpha$  (Figure 2) and increased the expression of CHOP protein and mRNA roughly proportional to their activity in the surrogate eIF2 $\alpha$  phosphorylation assay (Figure 3A and B). Consistently, *N*-phenyl,*N'*-(4-phenoxy)cyclohexylureas reduced the expression of cyclin D1 protein with minimal effect on the expression of its mRNA (Figure 3A and C), most likely owing to their specific effects on translation initiation. The compounds' activity on cyclin D1 protein expression correlated well with their activity in the surrogate eIF2 $\alpha$  phosphorylation assay. These data show a direct correlation between the activity of the compounds in the surrogate eIF2 $\alpha$  phosphorylation assay, their ability to induce the phosphorylation of endogenous eIF2 $\alpha$ , expression of CHOP protein and mRNA, and inhibit expression of oncogenic proteins.

#### **Dependence of activity of *N*-phenyl,*N'*-(4-phenoxy)cyclohexylureas on HRI—**

To determine if the molecular and cellular effects of *N*-phenyl,*N'*-(4-phenoxy)cyclohexylureas are mediated by HRI, we knock down its expression by transfecting reporter CRL-2813-pBISA-DL(ATF-4) cells used in the surrogate eIF2 $\alpha$  phosphorylation assay with siRNA targeting HRI or non-targeting siRNA, treated them with selected compounds and measured F/R ratio. As shown in Figure 4, siRNA targeting HRI significantly blunted activity of *N*-phenyl,*N'*-(4-phenoxy)cyclohexylureas in the surrogate eIF2 $\alpha$  phosphorylation assay compared to non-targeting siRNA.

To further determine the specificity of *N*-phenyl,*N'*-(4-phenoxy)cyclohexylureas for HRI, we utilized cell proliferation as a biological response paradigm. Cell proliferation is a very meaningful read-out for determining the specificity of a compound as it captures both on-target and off-target effects of the compound under study. If *N*-phenyl,*N'*-(4-phenoxy)cyclohexylureas specifically activate HRI and this activity is required for the inhibition of cell proliferation, then reducing the expression of HRI should blunt compounds' effect on cell proliferation. For this purpose, we knocked down expression of HRI in CRL-2813 human melanoma (~70% knockdown efficiency) and MCF-7 human breast cancer cells (~90% knockdown efficiency). These two cell lines were chosen because the HRI knockdown efficiency is lower in CRL-2813 than in MCF-7 cells providing a sort of dose-response data that may correlate knockdown efficiency with the resistance of cells to inhibition of cell proliferation by activators of HRI. Data shown in Figure 5 indicate that inhibition of cell proliferation by the *N*-phenyl, *N'*-(4-phenoxy)cyclohexylureas is mostly dependent on HRI and that it correlates with the HRI knockdown efficiency. Taken together, these data demonstrate that the *N*-phenyl,*N'*-(4-phenoxy)cyclohexylureas activate HRI, induce eIF2 $\alpha$  phosphorylation and reduce the amount of the ternary complex thereby inhibiting translation initiation and cell proliferation.


#### **Preliminary Hit-to-Lead Optimization**

Based on the screening and characterization of the Diversity Library described above we carried out a preliminary hit-to-lead optimization on the *N*-phenyl,*N'*-(4-phenoxy)cyclohexylurea scaffold **I** in which the *N'*-(4-phenoxy)cyclohexyl part of the

molecule was modified while the *N*-(*m*-CF<sub>3</sub>-phenyl) part was maintained. This process included two steps: 1) modification of substituents on the *N*-phenoxy ring (**I-14-20**, Table 2) and 2) exploration of substitution permutation on the cyclohexyl moiety (**III-1-5**, Table 3).

Similar to the SAR observed for the substituents on the *N'*-(4-phenoxy)cyclohexyl moiety (see Table 1) where the lipophilic electron withdrawing substituents CF<sub>3</sub>- and CF<sub>3</sub>O- and to a lesser extent halogen substituents resulted in the most potent analogs in both the surrogate eIF2 $\alpha$  phosphorylation and cell proliferation assays, their substitution on the phenoxy ring yielded more potent ureas **I-17-20** (Table 2) (cf. **I-17** and **I-18**; *p*-OCF<sub>3</sub> and *p*-CF<sub>3</sub>; F/R@<sub>30</sub> $\mu$ M = 14.42 and 25.12; SRB IC<sub>50</sub> = 0.69 and 0.46 $\mu$ M, respectively, with **I-5m** and **I-16**; *p*-F, and *p*-Cl; F/R@<sub>30</sub> $\mu$ M = 11.84 and 6.73; SRB IC<sub>50</sub> = 2.6 and 2.0 $\mu$ M, respectively). The analogs with highest maximum activity in the surrogate eIF2 $\alpha$  phosphorylation assay were **I-18** and **I-20** which displayed ~25-fold increase in F/R relative to vehicle. **I-18** also inhibited CRL-2813 human melanoma cell proliferation at sub- $\mu$ M concentrations. Note that even though E<sub>max</sub> of **I-20** is marginally higher, **I-18** has much higher activity across the entire concentration range tested (Figure 6).

Evidently, the substituted phenoxy moiety on the *N*-cyclohexyl is an integral part of the pharmacophore (Table 2). As presented in urea **I-18**, it is needed to generate the above high potency (Table 2). Elimination of the 4-trifluoromethylphenoxy (as in **III-1**) or 4-trifluoromethylphenyl (as in **III-2**) was sufficient to wipe out activity of these compounds in both the surrogate eIF2 $\alpha$  phosphorylation and cell proliferation assays (Table 3 and Figure 7). Moreover, insertion of an extra methylene that transforms the phenoxy into a benzyloxy moiety markedly reduced the activity (cf **III-3** and **I-5m**, F/R@<sub>30</sub> $\mu$ M = 9.58 and 11.84, respectively). Of interest was the effect of moving the 4- trifluoromethylphenoxy from position 4 to positions 2 or 3 on the cyclohexyl ring (cf. **I-18** with **III-4** and **III-5**, respectively) which, lead to a drastic reduction in the activity of compounds in both the surrogate eIF2 $\alpha$  phosphorylation and cell proliferation assays (IC<sub>50</sub> = 0.46 vs. 3.1 and 3.8  $\mu$ M, and F/R@<sub>30</sub> $\mu$ M = 25.12 vs. 5.89 and 4.52, respectively, Tables 2 and 3 and Figure 7). Taken together, data obtained with this series of ureas suggest that the phenoxy substitution is essential and its position on the cyclohexyl ring plays an important role in the hit-to-lead optimization process.



**Specificity of novel *N*-phenyl,*N'*-(4-phenoxy)cyclohexylurea compounds**—The improved activity of newly synthesized compounds in the surrogate eIF2 $\alpha$  phosphorylation and cell proliferations assays could either be due to better cell-penetration or higher affinity for their molecular target. It is also possible that the increased activity in the cell proliferation assay may be due, at least in part, to the increased off-target effects. We were also concerned that some compounds did not appear to have much activity in the surrogate eIF2 $\alpha$  phosphorylation assay at their IC<sub>50</sub> concentrations in the cell proliferation assay.

In general, if the affinity of compounds for their molecular target is increased this should result in higher specificity of the compounds in the cell proliferation assay. To demonstrate that this was indeed the case, we determined the dependence of the anti-proliferative effects of five selected compounds in these series on HRI. These five compounds, two with average and three with high potency, were tested in cell proliferation assay using CRL-2813 cells transfected with non-targeted siRNA or HRI-targeted siRNA as described in Figure 5. Evidently, IC<sub>50</sub> values in these studies cannot be directly compared to the corresponding values in Table 2 as the assay duration is reduced from five to three days, optimal time for suppression of gene expression by siRNA. As shown in Figure 8, two average potency compounds, **I-14** and **I-15**, displayed a significant dependence on HRI for inhibition of cell proliferation (~7 fold higher IC<sub>50</sub> values in cells transfected with HRI-targeting siRNA vs. in those transfected with non-targeting siRNA). This is a significant improvement in specificity toward the molecular target over initial hits shown in Figure 5 that displayed 1.7–2.2 fold higher IC<sub>50</sub> values in CRL-2813 cells transfected with HRI-targeting siRNA vs. those transfected with non-targeting siRNA. Compounds with higher potency in the surrogate eIF2 $\alpha$  phosphorylation and SRB assays also showed a very good target dependencies/specificities (~6, 7.5, and 5 fold higher IC<sub>50</sub> values in cells transfected with HRI-targeting siRNA vs. in those transfected with non-targeting siRNA for **I-17**, **I-18**, and **I-20**, respectively). These data indicate that our SAR studies resulted in the generation of more specific compounds. These data suggest that compounds' E<sub>max</sub> in the surrogate eIF2 $\alpha$  phosphorylation assay alone may not be sufficient to predict their specificity and that additional parameters such as C<sub>3X</sub> may also need to be considered.

To determine if the discrepancy in the active concentrations of some 1-(4-phenoxy-cyclohexyl)-3-(3-(trifluoromethyl)phenyl)urea in the surrogate eIF2 $\alpha$  phosphorylation and cell proliferation assays is due to differences in the length of these two assays we determined the activity of four compounds which display such discrepancy in the surrogate eIF2 $\alpha$  phosphorylation assay after 8, 16, or 32 hour incubation. As shown in Supplemental Figure 1, all four compounds displayed much higher activity after 32 hours of incubation compared to 8 or 16 hours. These data indicate that much of the discrepancy in the activity of some compounds in the two primary assays used in these studies are due to the differences in the duration of the assays and support our contention that there is a very good correlation between the activity of compounds in the surrogate eIF2 $\alpha$  phosphorylation and cell proliferation assays. One test of suitability of a compound for anti-cancer therapy is the selectivity for cancer cells compared to normal cells. We choose one moderately active, **I-6p**, and three highly active compounds, **I-17**, **I-18**, **I-20**, to determine if these series of *N*-phenyl,*N'*-cyclohexylphenoxy ureas can selectively inhibit proliferation of cancer cells. Dose-response studies in non-transformed NIH-3T3 fibroblast and CRL-2813 human melanoma cancer cell lines show that these compounds inhibit proliferation of cancer cells with 2.5- to 7-fold higher potency compared to that of non-transformed cells (Table 4). Among these compound **I-18** displayed the highest discrimination between cancer and non-cancerous cells. Taken together, data in Figure 8, Table 4 and Supplemental Figure 1 demonstrate that some of the more potent *N*-phenyl,*N'*-cyclohexylphenoxy ureas reported in here are highly potent and specific inducers of HRI activity.

## Conclusions

Structure-activity relationship analysis of the focused library of *N*-phenyl,*N'*-phenoxy-cyclohexylureas consistently shows that substitution of the *N*-phenyl and cyclohexylphenoxy moieties with lipophilic and strong electron withdrawing groups yield highly potent ureas in both the mechanistic surrogate eIF2 $\alpha$  phosphorylation and cell proliferation assays. While the *para*-position is strongly preferred in the *N*-phenyl moiety, there seems to be only a slight preference for it the phenoxy moiety. Moreover, substitution



of position 4 on the *N*-cyclohexyl by the phenoxy moiety emerges as the preferred arrangement relative to positions 2- and 3. Compounds **I-17** and **I-18** are the prototypes that may form the basis of advanced lead optimization efforts.

At the mechanistic level, we demonstrate that *N*-phenyl-*N'*-(4-phenoxy)cyclohexylureas induce phosphorylation of eIF2 $\alpha$  and expression of its downstream effector, CHOP protein and mRNA. These *N,N'*-disubstituted-ureas also inhibit expression of oncogenic proteins and cell proliferation. Most importantly, activity of these compounds in mechanistic surrogate eIF2 $\alpha$  phosphorylation assay as well as non-mechanistic cell proliferation assay is dependent on HRI. Consistently, there is a very good correlation between the activity of these agents in the mechanistic assays and cell proliferation assay. Taken together, these data indicate that *N*-phenyl,*N'*-(4-phenoxy)cyclohexylureas are mechanism specific agents suitable for further lead optimization to generate promising molecular probes for studying the role of HRI and eIF2 $\alpha$  phosphorylation in normal- and patho-biology and for pre-clinical leads suitable for development as drug candidates for the treatment of various human ailments such as cancer and  $\alpha$ - and  $\beta$ -thalassemia,

## Experimental Section

### Chemistry

All reagents and solvents were purchased from commercial sources and used without further purification. All the reaction solvents were anhydrous and the reactions were maintained under inert atmosphere. Thin layer chromatography (TLC) were run on pre-coated EMD silica gel 60 F<sub>254</sub> plates and observed under UV light at 254 nm and with basic potassium permanganate dip. All the reactions were monitored by LC-MS analysis on reverse phase (column Waters Symmetry C18, 2.1x 100 mm, 3.5  $\mu$ m particle size) using a Waters Alliance 2695 /Micromass ZQ or Agilent 1200 series system with UV detector (214 nm and 254 nm) and an Agilent 6130 quadrupole mass detector, with the binary system water/acetonitrile containing 0.1 % of formic acid as eluent. The purity of all final compounds was 95% as determined by analytical HPLC on reverse phase (column XBridge BEH130 C18, 4.6  $\times$  100 mm, 5  $\mu$ m particle size) using a Waters Alliance 2695 with the binary system water/acetonitrile containing 0.1 % of trifluoroacetic acid (TFA) as eluent. Column chromatography was performed with silica gel (230–400 mesh, grade 60, Fisher scientific, USA). Purifications by flash chromatography were performed on Biotage SP1 using silica gel pre-packed columns, (200–400 mesh), and were monitored by UV at 254 and 280 nm. Melting points were determined using a Mel-Temp Electrothermal apparatus and were uncorrected. Proton, carbon, and fluorine NMR analyses were performed on Topspin 300 MHz, Varian-400 or Varian-500 MHz spectrometers using DMSO- $d_6$  or CDCl<sub>3</sub> as solvent. Chemical shifts ( $\delta$ ) are reported in ppm relative to TMS as internal standard. The HR-MS analyses were performed at the FAS Center for Systems Biology, Harvard University. Compound **1b** was synthesized as described in literature<sup>34</sup>.

#### A. General Procedure for the synthesis of *N*-substituted cyclohexylamines, 1–

**9**—To a stirred solution of aminocyclohexanol, *n* = 2, 3 or 4, (230 mg, 2 mmol) in DMF (10 mL) at 0°C, was added 60% NaH in mineral oil (240 mg, 6 mmol). The reaction mixture was stirred at room temperature for 1 hour and then 1-fluoro-*n*-substituted benzene (2.4 mmol) was added. It was heated to 60°C for 2 hours then stirred for 16 hours at room temperature. The reaction mixture was diluted with ethyl acetate and washed with 10 mL of water (3 times) and brine. The organic layer was dried using sodium sulfate, filtered, and concentrated under vacuum. Then the product was purified using reversed phase column chromatography in gradient increase of methanol in 0.1% Formic acid solution<sup>31</sup>.

***trans*-4-(3-Fluorophenoxy)cyclohexylamine, 1:** Using General Procedure A employing *trans*-4-aminocyclohexanol and 1,3-difluorobenzene to afford **1** as a white solid, 94% (394 mg) yield, mp. 176°C. RP-HPLC (C18): 0 to 100% (ACN/Water/0.1% TFA) in 25 min,  $t_R$  = 9.966 min, purity of 99.2%;  $^1\text{H NMR}$  (399 MHz, DMSO- $d_6$ )  $\delta$  8.44 (s, 1H), 7.25 (q,  $J$  = 7.9 Hz, 1H), 6.75 (dddd,  $J$  = 31.0, 17.0, 8.8, 2.5 Hz, 2H), 4.63 (bs, 2H), 4.28 (tt,  $J$  = 9.3, 4.3 Hz, 1H), 3.07 – 2.78 (m, 1H), 1.99 (dd,  $J$  = 42.9, 11.4 Hz, 4H), 1.42 (dtd,  $J$  = 22.6, 12.9, 6.1 Hz, 4H).  $^{13}\text{C NMR}$  (100 MHz, DMSO)  $\delta$  166.63, 159.40, 131.38, 131.28, 112.60, 112.58, 107.88, 107.67, 103.79, 103.55, 75.00, 48.85, 29.82, 29.44.  $^{19}\text{F NMR}$  (376 MHz, DMSO)  $\delta$  -112.16. LCMS(ESI) for  $\text{C}_{12}\text{H}_{16}\text{FNO}$   $[\text{M}+\text{H}]^+$ : m/z calcd; 210.12, found; 209.90.

***trans*-4-(2-Fluorophenoxy)cyclohexylamine, 2:** Using General Procedure A employing *trans*-4-aminocyclohexanol and 1,2-difluorobenzene to afford **2** as a white solid, 90% (376 mg) yield, mp. 165°C. RP-HPLC (C18): 0 to 100% (ACN/Water/0.1% TFA) in 25 min,  $t_R$  = 9.543 min, purity of 99.7%;  $^1\text{H NMR}$  (399 MHz, DMSO- $d_6$ )  $\delta$  8.44 (s, 1H), 7.25 – 7.11 (m, 1H), 7.07 (t,  $J$  = 7.8 Hz, 1H), 7.04 – 6.83 (m, 1H), 4.99 (s, 2H), 4.35 – 4.03 (m, 1H), 3.14 – 2.71 (m, 1H), 2.22 – 1.71 (m, 4H), 1.43 (h,  $J$  = 11.5, 10.3 Hz, 4H).  $^{13}\text{C NMR}$  (100 MHz, DMSO)  $\delta$  166.73, 154.61, 125.43, 125.39, 122.24, 118.31, 116.99, 116.81, 76.59, 48.76, 29.93, 29.34.  $^{19}\text{F NMR}$  (376 MHz, DMSO)  $\delta$  -134.32. LCMS(ESI) for  $\text{C}_{12}\text{H}_{16}\text{FNO}$   $[\text{M}+\text{H}]^+$ : m/z calcd; 210.12, found; 209.84.

***trans*-4-(4-Chlorophenoxy)cyclohexylamine, 3:** Using General Procedure A employing *trans*-4-aminocyclohexanol and 1-chloro-4-fluorobenzene to afford **3** as a white solid, 85% (383 mg) yield, mp. 198°C. RP-HPLC (C18): 0 to 100% (ACN/Water/0.1% TFA) in 25 min,  $t_R$  = 19.302 min, purity of 100%;  $^1\text{H NMR}$  (399 MHz, DMSO- $d_6$ )  $\delta$  8.40 (s, 1H), 7.39 – 7.15 (m, 2H), 7.12 – 6.80 (m, 2H), 4.22 (dd,  $J$  = 9.8, 4.9 Hz, 1H), 3.63 (bs, 2H), 3.09 – 2.80 (m, 1H), 2.13 – 1.92 (m, 4H), 1.51 – 1.36 (m, 4H).  $^{13}\text{C NMR}$  (100 MHz, DMSO)  $\delta$  156.78, 129.94, 124.67, 118.17, 75.08, 48.95, 29.84, 29.68. LCMS(ESI) for  $\text{C}_{12}\text{H}_{16}\text{ClNO}$   $[\text{M}+\text{H}]^+$ : m/z calcd; 226.09, found; 225.99.

***trans*-4-(4-(Trifluoromethyl)phenoxy)cyclohexylamine, 4:** Using General Procedure A employing *trans*-4-aminocyclohexanol and 1-fluoro-4-(trifluoromethyl)benzene to afford **4** as a white solid, 95% (493 mg) yield, mp. 158°C. RP-HPLC (C18): 0 to 100% (ACN/Water/0.1% TFA) in 25 min,  $t_R$  = 11.864 min, purity of 99.8%;  $^1\text{H NMR}$  (399 MHz, DMSO- $d_6$ )  $\delta$  8.44 (s, 1H), 7.58 (d,  $J$  = 8.4 Hz, 2H), 7.11 (d,  $J$  = 8.5 Hz, 2H), 4.80 (s, 2H), 4.43 – 4.30 (m, 1H), 2.95 (dq,  $J$  = 11.1, 5.6, 5.1 Hz, 1H), 2.00 (dt,  $J$  = 47.0, 13.6 Hz, 4H), 1.43 (p,  $J$  = 16.1, 14.4 Hz, 4H).  $^{13}\text{C NMR}$  (100 MHz, DMSO)  $\delta$  166.70, 160.88, 127.58, 127.57, 116.56, 74.95, 48.77, 29.70, 29.35.  $^{19}\text{F NMR}$  (376 MHz, DMSO)  $\delta$  -60.28. LCMS(ESI) for  $\text{C}_{13}\text{H}_{16}\text{F}_3\text{NO}$   $[\text{M}+\text{H}]^+$ : m/z calcd; 260.12, found; 260.01.

***trans*-4-(4-(Trifluoromethoxy)phenoxy)cyclohexylamine, 5:** Using General Procedure A employing *trans*-4-aminocyclohexanol and 1-fluoro-4-(trifluoromethoxy)benzene to afford **5** as a white solid, 93% (512 mg) yield, mp. 147°C. RP-HPLC (C18): 0 to 100% (ACN/Water/0.1% TFA) in 25 min,  $t_R$  = 12.283 min, purity of 100%;  $^1\text{H NMR}$  (399 MHz, DMSO- $d_6$ )  $\delta$  8.44 (s, 1H), 7.21 (d,  $J$  = 8.6 Hz, 2H), 7.01 (d,  $J$  = 9.1 Hz, 2H), 5.58 (s, 2H), 4.25 (tt,  $J$  = 8.7, 4.2 Hz, 1H), 2.97 (dq,  $J$  = 12.5, 5.8 Hz, 1H), 2.34 – 1.77 (m, 4H), 1.43 (dt,  $J$  = 22.4, 12.3 Hz, 4H).  $^{13}\text{C NMR}$  (100 MHz, DMSO)  $\delta$  166.73, 156.76, 142.35, 123.09, 117.55, 75.14, 48.75, 29.76, 29.00.  $^{19}\text{F NMR}$  (376 MHz, DMSO)  $\delta$  -57.76. LCMS(ESI) for  $\text{C}_{13}\text{H}_{16}\text{F}_3\text{NO}_2$   $[\text{M}+\text{H}]^+$ : m/z calcd; 276.11, found; 276.16.

***trans*-4-(2-(Trifluoromethyl)phenoxy)cyclohexylamine, 6:** Using General Procedure A employing *trans*-4-aminocyclohexanol and 1-fluoro-2-(trifluoromethyl)benzene to afford **6** as a white solid, 90% (467 mg) yield, mp. 140°C. RP-HPLC (C18): 0 to 100% (ACN/Water/

0.1% TFA) in 25 min,  $t_R$  = 11.595 min, purity of 99%;  $^1\text{H}$  NMR (399 MHz, DMSO- $d_6$ )  $\delta$  8.45 (s, 1H), 7.53 (d,  $J$  = 7.7 Hz, 2H), 7.31 (d,  $J$  = 8.6 Hz, 1H), 7.01 (t,  $J$  = 7.6 Hz, 1H), 6.56 (bs, 2H), 4.45 (ddt,  $J$  = 10.1, 7.9, 4.0 Hz, 1H), 3.04 (ddt,  $J$  = 10.5, 7.6, 3.8 Hz, 1H), 2.14 – 1.82 (m, 4H), 1.47 (dddd,  $J$  = 25.2, 15.9, 12.8, 6.5 Hz, 4H).  $^{13}\text{C}$  NMR (100 MHz, DMSO)  $\delta$  166.90, 155.92, 134.62, 128.50, 127.42, 127.36, 125.79, 123.08, 120.82, 118.79, 118.49, 115.67, 75.43, 48.46, 29.38, 28.43.  $^{19}\text{F}$  NMR (376 MHz, DMSO)  $\delta$  –61.23. LCMS(ESI) for  $\text{C}_{13}\text{H}_{16}\text{F}_3\text{NO}$   $[\text{M}+\text{H}]^+$ :  $m/z$  calcd; 260.12, found; 260.08.

***trans*-4-(3-(Trifluoromethyl)phenoxy)cyclohexylamine, 7:** Using General Procedure A employing *trans*-4-aminocyclohexanol and 1-fluoro-3-(trifluoromethyl)benzene to afford **7** as a white solid, 92% (477 mg) yield, mp. 133°C. RP-HPLC (C18): 0 to 100% (ACN/Water/0.1% TFA) in 25 min,  $t_R$  = 11.761 min, purity of 99%;  $^1\text{H}$  NMR (399 MHz, DMSO- $d_6$ )  $\delta$  8.44 (s, 1H), 7.47 (t,  $J$  = 8.0 Hz, 1H), 7.33 – 7.05 (m, 2H), 6.00 (s, 2H), 4.39 (td,  $J$  = 9.9, 5.0 Hz, 1H), 3.15 – 2.85 (m, 1H), 2.29 – 1.77 (m, 4H), 1.67 – 1.24 (m, 4H).  $^{13}\text{C}$  NMR (100 MHz, DMSO)  $\delta$  166.72, 158.22, 131.38, 120.29, 117.66, 113.04, 74.94, 48.71, 29.67, 28.81.  $^{19}\text{F}$  NMR (376 MHz, DMSO)  $\delta$  –61.62. LCMS(ESI) for  $\text{C}_{13}\text{H}_{16}\text{F}_3\text{NO}$   $[\text{M}+\text{H}]^+$ :  $m/z$  calcd; 260.12, found; 260.08.

***trans*-2-(4-(Trifluoromethyl)phenoxy)cyclohexylamine, 8:** Using General Procedure A employing 2-aminocyclohexanol and 1-fluoro-4-(trifluoromethyl)benzene to afford **8** as a white solid, 47% (246 mg) yield, mp. 131°C. RP-HPLC (C18): 0 to 100% (ACN/Water/0.1% TFA) in 25 min,  $t_R$  = 11.895 min, purity of 100%;  $^1\text{H}$  NMR (399 MHz, DMSO- $d_6$ )  $\delta$  8.41 (s, 1H), 7.62 (d,  $J$  = 8.0 Hz, 2H), 7.18 (d,  $J$  = 8.1 Hz, 2H), 6.09 (bs, 2H), 4.92–4.75 (m, 1H), 3.29 (d,  $J$  = 8.0 Hz, 1H), 2.03 – 1.89 (m, 1H), 1.88 – 1.59 (m, 3H), 1.52 (q,  $J$  = 7.0, 6.6 Hz, 1H), 1.44 – 1.24 (m, 3H).  $^{13}\text{C}$  NMR (100 MHz, DMSO)  $\delta$  166.57, 160.66, 127.54, 127.49, 117.33, 117.01, 74.25, 51.13, 27.00, 26.84, 23.26, 19.82.  $^{19}\text{F}$  NMR (376 MHz, DMSO)  $\delta$  –60.45. LCMS(ESI) for  $\text{C}_{13}\text{H}_{16}\text{F}_3\text{NO}$   $[\text{M}+\text{H}]^+$ :  $m/z$  calcd; 260.12, found; 260.01.

***trans*-3-(4-(Trifluoromethyl)phenoxy)cyclohexylamine, 9:** Using General Procedure A employing 3-aminocyclohexanol and 1-fluoro-4-(trifluoromethyl)benzene to afford **9** as a white solid, 38% (197 mg) yield, mp. 117°C. RP-HPLC (C18): 0 to 100% (ACN/Water/0.1% TFA) in 25 min,  $t_R$  = 11.877 min, purity of 100%;  $^1\text{H}$  NMR (399 MHz, DMSO- $d_6$ )  $\delta$  8.42 (s, 1H), 7.59 (d,  $J$  = 8.5 Hz, 2H), 7.11 (d,  $J$  = 8.5 Hz, 2H), 6.53 (s, 2H), 5.08 – 4.73 (m, 1H), 3.26 (td,  $J$  = 9.5, 8.1, 4.5 Hz, 1H), 2.35 – 1.42 (m, 8H).  $^{13}\text{C}$  NMR (100 MHz, DMSO)  $\delta$  166.74, 160.45, 127.59, 127.45, 122.02, 121.71, 116.74, 72.04, 45.90, 34.21, 30.15, 28.59, 19.07.  $^{19}\text{F}$  NMR (376 MHz, DMSO)  $\delta$  –60.48. LCMS(ESI) for  $\text{C}_{13}\text{H}_{16}\text{F}_3\text{NO}$   $[\text{M}+\text{H}]^+$ :  $m/z$  calcd; 260.12, found; 260.08.

***trans*-4-((4-Fluorobenzyl)oxy)cyclohexylamine, 10:** 2 mmol of *trans*-4-aminocyclohexanol was dissolved in 5 mL of dry Methanol, then 1.1 equiv of  $\text{Boc}_2\text{O}$  were dissolved in 5 mL methanol and added drop wise at room temperature. The reaction was stirred until completion by TLC, then solvent was evaporated to dryness. The produced crude was redissolved in 5 mL of dry THF, and cooled to 0°C. Then 2.2 mmol of 60% NaH in mineral oil were added. The reaction mixture was stirred at room temperature for 30 min and then 1.5 equiv of 4-fluorobenzylbromide was added. The reaction was stirred for 16 hours at room temperature. The reaction mixture was diluted with ethyl acetate and washed with 10 mL of water (3 times) and brine. The organic layer was dried using sodium sulfate, filtered, and concentrated under vacuum. Then the product was dissolved in 2 mL of DCM/TFA, 1:1, solvent mixture and stirred for 1 hr. The solvent was evaporated to dryness and the obtained solid was purified using reversed phase column chromatography in gradient increase of methanol in 0.1% Formic acid solution. White solid, 96% (429 mg) yield, mp. 166°C. RP-HPLC (C18): 0 to 100% (ACN/Water/0.1% TFA) in 25 min,  $t_R$  = 9.528 min,

purity of 97.8%;  $^1\text{H}$  NMR (399 MHz,  $\text{DMSO-}d_6$ )  $\delta$  7.33 (dd,  $J = 8.1, 5.5$  Hz, 2H), 7.13 (t,  $J = 8.6$  Hz, 2H), 6.90 (bs, 2H), 4.46 (s, 2H), 4.28–4.21 (m, 1H), 3.31–3.28 (m, 1H), 2.98 (dt,  $J = 10.9, 5.9$  Hz, 1H), 1.97 (dd,  $J = 43.0, 12.0$  Hz, 4H), 1.37–1.15 (m, 4H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{DMSO}$ )  $\delta$  163.31, 135.33, 130.06, 129.98, 115.71, 115.50, 76.05, 69.07, 49.23, 30.07, 29.85, 28.84.  $^{19}\text{F}$  NMR (376 MHz,  $\text{DMSO}$ )  $\delta$  –115.88. LCMS(ESI) for  $\text{C}_{13}\text{H}_{18}\text{FNO}$  [ $\text{M} + \text{H}$ ] $^+$ :  $m/z$  calcd; 224.14, found; 223.81.

***cis*-Methyl 2-(3-(4-(4-fluorophenoxy)cyclohexyl)ureido)benzoate, I-11o:** To a stirring solution of *cis*-4-(4-fluorophenoxy)cyclohexylamine, **1b**<sup>37</sup>, (20 mg, 0.09 mmol) in dichloromethane (2 mL) under nitrogen was added methyl 2-isocyanatobenzoate (15 mg, 0.08 mmol). The mixture was maintained at room temperature for 16 h and the reaction monitored for completion by TLC. Crude mixture was washed with brine and extracted using dichloromethane, dried under magnesium sulfate and column chromatographed using hexane and ethyl acetate gradient to obtain desired product as white amorphous solid (22 mg, 59% yield).  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  10.33 (s, 1H), 8.53 (d,  $J = 8.5$  Hz, 1H), 7.98 (d,  $J = 8.0$  Hz, 1H), 7.49 (dd,  $J = 8.5$  Hz, 7.5 Hz, 1H), 6.99–6.94 (m, 3H), 6.86–6.84 (m, 2H), 4.72 (d,  $J = 8.0$  Hz, 1H), 4.40 (s, 1H), 3.90 (s, 3H), 3.79–3.75 (m, 1H), 2.04–2.00 (m, 2H), 1.86–1.84 (m, 2H), 1.74–1.66 (m, 4H);  $^{13}\text{C}$  NMR  $\delta$  169.46, 158.41, 156.51, 154.35, 153.62, 143.59, 134.84, 130.90, 120.75, 119.54, 117.60, 117.54, 116.16, 115.98, 113.73, 72.16, 52.35, 48.35, 28.56, 28.36, 28.04;  $^{19}\text{F}$  NMR (376 MHz,  $\text{DMSO}$ )  $\delta$  –40.61. LCMS for  $\text{C}_{21}\text{H}_{23}\text{FN}_2\text{O}_4$  [ $\text{M} + \text{H}$ ] $^+$ :  $m/z$  calcd; 387.41, found; 387.20.

***cis*-2-(3-(4-(4-Fluorophenoxy)cyclohexyl)ureido)benzoic acid, I-12o:** To a solution of urea **I-11o** (14 mg, 0.04 mmol) in 1 mL of acetonitrile was added lithium hydroxide (3 mg, 0.11 mmol) in water (0.3 mL) and reaction mixture was stirred at room temperature for 24 hours. Solvent was evaporated and the crude mixture was dissolved in methanol and filtered through a silica pipette to obtain pure product as white solid (10 mg, 74%).  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  10.69 (s, 1H), 8.13 (d,  $J = 8.0$  Hz, 1H), 7.54 (t,  $J = 8.0$  Hz, 1H), 7.21 (t,  $J = 7.5$  Hz, 1H), 7.14 (d,  $J = 8.5$  Hz, 1H), 6.98 (d,  $J = 7.0$  Hz, 4H), 6.04 (s, 1H), 5.56 (s, 1H), 5.03 (t,  $J = 12.5$  Hz, 1H), 4.51 (s, 1H), 3.05–2.98 (m, 2H), 2.22–2.19 (m, 2H), 1.71–1.66 (m, 2H), 1.56–1.54 (m, 2H);  $^{13}\text{C}$  NMR  $\delta$  163.53, 158.44, 153.76, 152.56, 139.08, 135.03, 128.68, 123.38, 118.04, 117.98, 116.13, 115.95, 115.17, 114.99, 71.41, 53.18, 29.76, 23.09;  $^{19}\text{F}$  NMR (376 MHz,  $\text{DMSO}$ )  $\delta$  –40.64. LCMS for  $\text{C}_{20}\text{H}_{21}\text{FN}_2\text{O}_4$  [ $\text{M} + \text{H}$ ] $^+$ :  $m/z$  calcd; 373.39, found; 373.15.

## B. General Procedure for synthesis of the *N*-aryl,*N'*-cyclohexylureas, I-14-20 and III-1-5

—To a stirred solution of 3-(trifluoromethyl)phenylisocyanate (1 mmol) in dry DMF (2 mL) and triethylamine (1 mmol), the desired amine (1 mmol) was added and the reaction was left at RT for 16 hrs. The reaction mixture was treated with DDW(5 mL) and the formed precipitate was collected, washed with water, and re-crystallized twice from methanol/water. In some cases further purification by reversed phase column chromatography employing a linear gradient of (0.1% formic acid/water) in methanol, (0%–100%) was needed to achieve purity >95%.

***trans*-1-(4-(2-Fluorophenoxy)cyclohexyl)-3-(3-(trifluoromethyl)phenyl)urea, I-14:** Using General Procedure B employing *trans*-4-(2-fluorophenoxy)cyclohexylamine **2**, to afford **I-14** as a white solid, 56% (220 mg) yield, mp. 171°C. RP-HPLC (C18): 0 to 100% (ACN/Water/0.1%TFA) in 25 min,  $t_R = 18.365$  min, purity of 99%;  $^1\text{H}$  NMR (300 MHz,  $\text{DMSO-}d_6$ )  $\delta$  8.63 (s, 1H), 7.94 (s, 1H), 7.51–7.33 (m, 2H), 7.24 (dq,  $J = 20.4, 7.1, 6.4$  Hz, 2H), 6.73 ((dt,  $J = 16.5, 11.0$  Hz, 2H m, 3H), 6.24 (d,  $J = 5.5$  Hz, 1H), 4.34 (q,  $J = 9.0, 8.4$  Hz, 1H), 3.56–3.45 (m, 1H), 2.03–1.87(m, 4H), 1.49–1.31 (m, 4H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{DMSO}$ )  $\delta$  155.08, 141.97, 130.38, 125.38, 122.11, 121.74, 118.26, 117.00, 116.82, 114.18, 76.74,

47.91, 30.43.  $^{19}\text{F}$  NMR (376 MHz, DMSO)  $\delta$  -61.80, -134.26. HRMS(ESI) for  $\text{C}_{20}\text{H}_{20}\text{F}_4\text{N}_2\text{O}_2$   $[\text{M}+\text{H}]^+$ : m/z calcd; 397.15337, found; 397.15317.

***trans*-1-(4-(3-Fluorophenoxy)cyclohexyl)-3-(3-(trifluoromethyl)phenyl)urea, I-15:** Using General Procedure B employing *trans*-4-(3-fluorophenoxy)cyclohexylamine **1**, to afford **I-15** as a white solid, 66% (260 mg) yield, mp. 193°C. RP-HPLC (C18): 0 to 100% (ACN/Water/0.1% TFA) in 25 min,  $t_{\text{R}}$  = 18.857 min, purity of 100%;  $^1\text{H}$  NMR (300 MHz, DMSO- $d_6$ )  $\delta$  8.64 (s, 1H), 7.94 (s, 1H), 7.58 (d,  $J$  = 8.4 Hz, 2H), 7.41 (d,  $J$  = 5.5 Hz, 2H), 7.18 (d,  $J$  = 5.9 Hz, 1H), 7.10 (d,  $J$  = 8.4 Hz, 2H), 6.24 (d,  $J$  = 7.5 Hz, 1H), 4.57- 4.33 (m, 1H), 3.55-3.46 (m, 1H), 2.13-1.75 (m, 4H), 1.41 (dp,  $J$  = 23.6, 12.0 Hz, 4H).  $^{13}\text{C}$  NMR (100 MHz, DMSO)  $\delta$  155.06, 141.96, 131.38, 131.26, 130.39, 121.74, 117.83, 114.14, 112.59, 107.58, 103.49, 75.16, 47.96, 30.54, 30.29.  $^{19}\text{F}$  NMR (376 MHz, DMSO)  $\delta$  -61.78, -112.16. HRMS(ESI) for  $\text{C}_{20}\text{H}_{20}\text{F}_4\text{N}_2\text{O}_2$   $[\text{M}+\text{H}]^+$ : m/z calcd; 397.15337, found; 397.15429.

***trans*-1-(4-(4-Chlorophenoxy)cyclohexyl)-3-(3-(trifluoromethyl)phenyl)urea, I-16:** Using General Procedure B employing *trans*-4-(4-chlorophenoxy)cyclohexylamine **3**, to afford **I-16** as a white solid, 50% (206 mg) yield, mp. 244°C. RP-HPLC (C18): 0 to 100% (ACN/Water/0.1% TFA) in 25 min,  $t_{\text{R}}$  = 19.617 min, purity of 100%;  $^1\text{H}$  NMR (300 MHz, DMSO- $d_6$ ):  $\delta$  8.65 (s, 1H), 7.95 (s, 1H), 7.42 (d,  $J$  = 7.9 Hz, 2H), 7.27 (dd,  $J$  = 9.0, 3.3 Hz, 2H), 7.19 (d,  $J$  = 6.8 Hz, 1H), 6.95 (dd,  $J$  = 8.7, 3.5 Hz, 2H), 6.25 (d,  $J$  = 4.0 Hz, 1H), 4.32 - 4.27 (m, 1H), 3.55 - 3.48 (m, 1H), 2.50 - 1.90 (m, 4H), 1.48-1.29 (m, 4H).  $^{13}\text{C}$  NMR (100 MHz, DMSO)  $\delta$  156.84, 155.06, 141.96, 130.40, 129.92, 124.70, 121.73, 118.08, 117.85, 114.14, 75.13, 47.96, 30.57, 30.30.  $^{19}\text{F}$  NMR (376 MHz, DMSO)  $\delta$  -61.79. HRMS(ESI) for  $\text{C}_{20}\text{H}_{20}\text{ClF}_3\text{N}_2\text{O}_2$   $[\text{M}+\text{H}]^+$ : m/z calcd; 413.12382, found; 413.12507.

***trans*-1-(4-(4-(trifluoromethoxy)phenoxy)cyclohexyl)-3-(3-(trifluoromethyl)phenyl)urea, I-17:** Using General Procedure B employing *trans*-4-(4-(trifluoromethoxy)phenoxy)cyclohexylamine **5**, to afford **I-17** as a white solid, 54% (251 mg) yield, mp. 190°C. RP-HPLC (C18): 0 to 100% (ACN/Water/0.1% TFA) in 25 min,  $t_{\text{R}}$  = 20.231 min, purity of 100%;  $^1\text{H}$  NMR (399 MHz, DMSO- $d_6$ )  $\delta$  8.66 (s, 1H), 7.96 (s, 1H), 7.46 - 7.41 (m, 2H), 7.39-7.04 (m, 3H), 7.01 (d,  $J$  = 8.5 Hz, 2H), 6.25 (d,  $J$  = 7.6 Hz, 1H), 4.35-4.30 (m, 1H), 3.54-3.49 (dd,  $J$  = 13.8, 7.3 Hz, 1H), 2.04 - 1.90 (m, 4H), 1.47-1.33 (m, 4H).  $^{13}\text{C}$  NMR (100 MHz, DMSO)  $\delta$  156.88, 155.07, 141.96, 130.36, 123.14, 121.71, 117.47, 114.14, 75.32, 47.96, 30.56, 30.30.  $^{19}\text{F}$  NMR (376 MHz, DMSO)  $\delta$  -57.78, -61.87. LCMS(ESI) for  $\text{C}_{21}\text{H}_{20}\text{F}_6\text{N}_2\text{O}_3$   $[\text{M}+\text{H}]^+$ : m/z calcd; 463.13, found; 463.11.

***trans*-1-(4-(4-(Trifluoromethyl)phenoxy)cyclohexyl)-3-(3-(trifluoromethyl)phenyl)urea, I-18:** Using General Procedure B employing *trans*-4-(4-(trifluoromethyl)phenoxy)cyclohexylamine **4**, to afford **I-18** as a white solid, 43% (194 mg) yield, mp. 176°C. RP-HPLC (C18): 0 to 100% (ACN/Water/0.1% TFA) in 25 min,  $t_{\text{R}}$  = 19.617 min, purity of 100%;  $^1\text{H}$  NMR (399 MHz, DMSO- $d_6$ )  $\delta$  8.64 (s, 1H), 7.94 (s, 1H), 7.58 (d,  $J$  = 8.1 Hz, 2H), 7.41 (d, 2H), 7.25-7.15 (m, 1H), 7.09 (t,  $J$  = 9.3 Hz, 2H), 6.26 (d,  $J$  = 7.5 Hz, 1H), 4.58-4.31 (m, 1H), 3.72 - 3.39 (m, 1H), 2.25 - 1.73 (m, 4H), 1.53-1.29 (m, 4H).  $^{13}\text{C}$  NMR (100 MHz, DMSO)  $\delta$  160.97, 155.06, 141.94, 138.79, 130.44, 127.64, 121.76, 116.00, 114.13, 75.08, 47.91, 30.53, 30.22.  $^{19}\text{F}$  NMR (376 MHz, DMSO)  $\delta$  -60.21, -61.78. HRMS(ESI) for  $\text{C}_{21}\text{H}_{20}\text{F}_6\text{N}_2\text{O}_2$   $[\text{M}+\text{H}]^+$ : m/z calcd; 447.15017, found; 447.15126.

***trans*-1-(4-(2-(Trifluoromethyl)phenoxy)cyclohexyl)-3-(3-(trifluoromethyl)phenyl)urea, I-19:** Using General Procedure B employing *trans*-4-(2-(trifluoromethyl)phenoxy)cyclohexylamine **6**, to afford **I-19** as a white solid, 69 % (308 mg) yield, mp. 121°C. RP-HPLC (C18): 0 to 100% (ACN/Water/0.1% TFA) in 25 min,  $t_{\text{R}}$  = 19.868 min, purity of 99%;  $^1\text{H}$  NMR (400 MHz, DMSO- $d_6$ )  $\delta$  8.69 (s, 1H), 7.96 (s, 1H),



7.59 (d,  $J = 7.7$  Hz, 2H), 7.45 – 7.41 (m, 2H), 7.31 (d,  $J = 8.6$  Hz, 1H), 7.20 (d,  $J = 7.7$  Hz, 1H), 7.06 (t,  $J = 7.6$  Hz, 1H), 6.36 (d,  $J = 7.8$  Hz, 1H), 4.56 (td,  $J = 9.4, 4.8$  Hz, 1H), 3.56 (dtt,  $J = 15.2, 9.9, 4.9$  Hz, 1H), 2.05–1.87 (m, 4H), 1.54–1.32 (m, 4H).  $^{13}\text{C}$  NMR (100 MHz, DMSO)  $\delta$  154.19, 153.28, 147.42, 146.89, 140.15, 132.83, 128.55, 128.14, 125.66, 119.89, 118.88, 116.01, 113.71, 112.30, 73.64, 45.71, 28.09, 27.88.  $^{19}\text{F}$  NMR (376 MHz, DMSO)  $\delta$  –62.10, –62.71. HRMS(ESI) for  $\text{C}_{21}\text{H}_{20}\text{F}_6\text{N}_2\text{O}_2$   $[\text{M}+\text{H}]^+$ :  $m/z$  calcd; 447.15017, found; 447.15147.

**trans-1-(4-(3-(Trifluoromethyl)phenoxy)cyclohexyl)-3-(3-(trifluoromethyl)phenyl)urea, I-20:**

Using General Procedure B employing *trans*-4-(3-(trifluoromethyl)phenoxy)cyclohexylamine **7**, to afford **I-20** as a white solid, 59 % (264 mg) yield, mp. 160°C. RP-HPLC (C18): 0 to 100% (ACN/Water/0.1%TFA) in 25 min,  $t_{\text{R}} = 20.083$  min, purity of 99%;  $^1\text{H}$  NMR (300 MHz, DMSO- $d_6$ )  $\delta$  8.67 (s, 1H), 7.94 (s, 1H), 7.64 – 7.31 (m, 3H), 7.35 – 7.07 (m, 4H), 6.26 (d,  $J = 7.5$  Hz, 1H), 4.45 (tt,  $J = 9.5, 4.0$  Hz, 1H), 3.72 – 3.38 (m, 1H), 2.01 – 1.76 (m, 4H), 1.63 – 1.21 (m, 4H).  $^{13}\text{C}$  NMR (100 MHz, DMSO)  $\delta$  155.10, 142.00, 131.37, 130.40, 121.75, 120.37, 117.73, 114.23, 112.97, 75.24, 47.93, 30.48, 30.24.  $^{19}\text{F}$  NMR (376 MHz, DMSO)  $\delta$  –61.50, –61.77. HRMS(ESI) for  $\text{C}_{21}\text{H}_{20}\text{F}_6\text{N}_2\text{O}_2$   $[\text{M}+\text{H}]^+$ :  $m/z$  calcd; 447.15017, found; 447.15145.

**1-Cyclohexyl-3-(3-(trifluoromethyl)phenyl)urea, III-1:**

Using General Procedure B employing cyclohexylamine to afford **III-1** as a white solid, 63% (180 mg) yield, mp. 180°C. RP-HPLC (C18): 0 to 100% (ACN/Water/0.1%TFA) in 25 min,  $t_{\text{R}} = 16.943$  min, purity of 98%;  $^1\text{H}$  NMR (399 MHz, DMSO- $d_6$ )  $\delta$  8.62 (s, 1H), 7.95 (s, 1H), 7.42 (t,  $J = 7.4$  Hz, 2H), 7.16 (d,  $J = 7.4$  Hz, 1H), 6.14 (d,  $J = 8.3$  Hz, 1H), 3.47 (m, 1H), 1.78 (d,  $J = 12.0$  Hz, 2H), 1.62 (d,  $J = 13.2$  Hz, 3H), 1.50 (d,  $J = 13.4$  Hz, 1H), 1.21 (dp,  $J = 34.6, 12.4, 11.8$  Hz, 5H).  $^{13}\text{C}$  NMR (100 MHz, DMSO)  $\delta$  154.92, 142.04, 130.30, 121.63, 117.73, 114.11, 48.43, 33.49, 25.85, 25.01.  $^{19}\text{F}$  NMR (376 MHz, DMSO)  $\delta$  –61.91. HRMS(ESI) for  $\text{C}_{14}\text{H}_{17}\text{F}_3\text{N}_2\text{O}$   $[\text{M}+\text{H}]^+$ :  $m/z$  calcd; 287.13657, found; 287.13707.

**trans-1-(4-Hydroxycyclohexyl)-3-(3-(trifluoromethyl)phenyl)urea, III-2:**

Using General Procedure B employing *trans*-4-aminocyclohexanol, to afford **III-2** as a white solid, 59 % (178 mg) yield, mp. 249°C. RP-HPLC (C18): 0 to 100% (ACN/Water/0.1%TFA) in 25 min,  $t_{\text{R}} = 12.467$  min, purity of 100%;  $^1\text{H}$  NMR (399 MHz, DMSO- $d_6$ )  $\delta$  8.62 (s, 1H), 7.94 (s, 1H), 7.41 (td,  $J = 10.8, 7.2$  Hz, 2H), 7.17 (d,  $J = 7.1$  Hz, 1H), 6.09 (d,  $J = 8.3$  Hz, 1H), 4.52–4.47 (m, 1H), 3.39–3.20 (m, 2H), 1.85 – 1.78 (m, 4H), 1.24 – 1.13 (m, 4H).  $^{13}\text{C}$  NMR (100 MHz, DMSO)  $\delta$  155.07, 142.01, 130.31, 130.00, 121.71, 117.79, 114.19, 68.68, 48.43, 34.45, 31.32.  $^{19}\text{F}$  NMR (376 MHz, DMSO)  $\delta$  –61.88. HRMS(ESI) for  $\text{C}_{14}\text{H}_{17}\text{F}_3\text{N}_2\text{O}_2$   $[\text{M}+\text{H}]^+$ :  $m/z$  calcd; 303.13149, found; 303.13204.

**trans-1-(4-((4-Fluorobenzyl)oxy)cyclohexyl)-3-(3-(trifluoromethyl)phenyl)urea, III-3:**

Using General Procedure B employing *trans*-4-((4-fluorobenzyl)oxy)cyclohexylamine **10**, to afford **III-3** as a white solid, 33% (136 mg) yield, mp. 162°C. RP-HPLC (C18): 0 to 100% (ACN/Water/0.1%TFA) in 25 min,  $t_{\text{R}} = 18.230$  min, purity of 95%;  $^1\text{H}$  NMR (300 MHz, DMSO- $d_6$ )  $\delta$  8.63 (s, 1H), 7.93 (s, 1H), 7.41–7.39 (m, 2H), 7.34 – 7.30 (m, 1H), 7.18 – 7.09 (m, 3H), 6.14 (d,  $J = 7.7$  Hz, 1H), 4.44 (s, 2H), 3.42 (dd,  $J = 12.3, 5.4$  Hz, 1H), 3.49–3.36 (m, 1H), 3.35–3.33 (m, 1H), 2.09 – 1.71 (m, 4H), 1.24 (dq,  $J = 21.0, 11.0$ , 4H).  $^{13}\text{C}$  NMR (100 MHz, DMSO)  $\delta$  155.12, 142.09, 136.18, 130.36, 130.03, 129.95, 121.68, 117.71, 115.70, 115.49, 76.42, 68.94, 48.21, 30.90, 30.85.  $^{19}\text{F}$  NMR (376 MHz, DMSO)  $\delta$  –61.78, –116.01. LCMS(ESI) for  $\text{C}_{21}\text{H}_{22}\text{F}_4\text{N}_2\text{O}_2$   $[\text{M}+\text{H}]^+$ :  $m/z$  calcd; 411.16, found; 411.12.

**trans-1-(2-(4-(Trifluoromethyl)phenoxy)cyclohexyl)-3-(3-(trifluoromethyl)phenyl)urea, III-4:**

Using General Procedure B employing *trans*-2-(4-

(trifluoromethyl)phenoxy)cyclohexylamine **8**, to afford **III-4** as a white solid, 79 % (354 mg) yield, mp. 58°C. RP-HPLC (C18): 0 to 100% (ACN/Water/0.1% TFA) in 25 min,  $t_R$  = 20.047 min, purity of 97%;  $^1\text{H}$  NMR (500 MHz, DMSO- $d_6$ )  $\delta$  8.84 (s, 1H), 7.92 (s, 1H), 7.61 (d,  $J$  = 8.4 Hz, 2H), 7.45 – 7.31 (m, 2H), 7.18 (d,  $J$  = 8.4 Hz, 3H), 6.38 (d,  $J$  = 8.0 Hz, 1H), 4.70 (dt,  $J$  = 5.1, 2.58 Hz, 1H), 3.96-3.77 (m, 1H), 1.99 – 1.84 (m, 1H), 1.67 (q,  $J$  = 4.5, 4.0 Hz, 3H), 1.65 (dd,  $J$  = 14.5, 7.8 Hz, 1H), 1.46-1.31 (m, 3H).  $^{13}\text{C}$  NMR (100 MHz, DMSO)  $\delta$  16.77, 154.70, 147.32, 141.57, 130.21, 127.36, 121.33, 116.72, 75.26, 49.83, 28.15, 27.56, 23.83, 19.91.  $^{19}\text{F}$  NMR (376 MHz, DMSO)  $\delta$  -59.88, -61.42. HRMS(ESI) for  $\text{C}_{21}\text{H}_{20}\text{F}_6\text{N}_2\text{O}_2$   $[\text{M}+\text{H}]^+$ :  $m/z$  calcd; 447.15017, found; 447.15122.

**trans-1-(3-(4-(Trifluoromethyl)phenoxy)cyclohexyl)-3-(3-(trifluoromethyl)phenyl)urea, III-5:** Using General Procedure B employing *trans*-3-(4-(trifluoromethyl)phenoxy)cyclohexylamine **9**, to afford **III-5** as a white solid, 69% (306 mg) yield, mp. 62°C. RP-HPLC (C18): 0 to 100% (ACN/Water/0.1% TFA) in 25 min,  $t_R$  = 20.183 min, purity of 100%;  $^1\text{H}$  NMR (399 MHz, DMSO- $d_6$ )  $\delta$  8.74 (s, 1H), 7.94 (s, 1H), 7.60 (d,  $J$  = 8.6 Hz, 2H), 7.42 (dt,  $J$  = 15.5, 8.2 Hz, 2H), 7.17 (d,  $J$  = 7.7 Hz, 1H), 7.10 (d,  $J$  = 8.5 Hz, 2H), 6.35 (d,  $J$  = 8.1 Hz, 1H), 4.80 (s, 1H), 3.90 (dp,  $J$  = 14.0, 5.4, 4.6 Hz, 1H), 2.01-1.91 (m, 1H), 1.87-1.69 (m, 2H), 1.68-1.50 (m, 4H), 1.44-1.21(m, 1H).  $^{13}\text{C}$  NMR (100 MHz, DMSO)  $\delta$  160.76, 155.01, 142.00, 130.33, 127.66, 127.75, 117.82, 116.61, 114.19, 73.09, 44.70, 36.55, 32.45, 29.33, 19.90.  $^{19}\text{F}$  NMR (376 MHz, DMSO)  $\delta$  -60.34, -61.86. HRMS(ESI) for  $\text{C}_{21}\text{H}_{20}\text{F}_6\text{N}_2\text{O}_2$   $[\text{M}+\text{H}]^+$ :  $m/z$  calcd; 447.15017, found; 447.15159.

### Plasmids and Ternary complex assay

The dual luciferase expression vector and other plasmids used for these studies are described in<sup>32</sup>. The ternary complex assay, surrogate of eIF2 $\alpha$  phosphorylation, has been described elsewhere<sup>25</sup>. Briefly, the pBISA vector, which contains seven copies of the tetracycline-regulated transactivator response element (TRE), is flanked on both sides by human cytomegalovirus (CMV) minimal promoters allowing bi-directional transcription and two MCSs. Firefly and renilla luciferases were subcloned into MCS-I and MCS-II, respectively. This plasmid, designated pBISA-DL, transcribes two mRNAs that contain the 90 nucleotide plasmid derived 5'UTR (same sequence in both mRNAs), and the ORF encoding either firefly or renilla luciferase followed by a polyadenylation sequence. This plasmid was further modified by inserting the 5'UTR of ATF-4 mRNA into MCS-I in front of the firefly luciferase mRNA. Transcription from this unit generates an mRNA that contains the firefly luciferase ORF preceded by a 5'UTR composed of 90 nucleotides derived from the plasmid and 267 nucleotides derived from the 5'UTR of ATF-4 mRNA. Transcription from the other unit generates an mRNA that contains the renilla luciferase ORF preceded only by the 90-nucleotide plasmid-derived sequence in the 5'UTR (pBISA-DL(ATF-4))<sup>25</sup>.

### Dual luciferase (DLR) assay

Cells expressing firefly and renilla luciferases were assayed with a *dual glow* luciferase assay kit, per manufacturer's instruction (Promega Inc., Madison, WI). The data calculations were carried out as the ratio of firefly to renilla luciferase signal. Dose-response curves were obtained and triplicate data points were fitted to the logistical sigmoidal model using nonlinear least-squares regression performed in GraphPad Prism 6, where  $E_{\text{max}}$  is the maximal stimulatory effect of F/R Ratio, and  $C_{3X}$  is the concentration at which F/R ratio=3 on the curve.

### Stable and transient transfection

Stable cell lines utilized in this study are generated as described elsewhere<sup>22</sup>. Briefly, cells were seeded at the density of  $10^5$  in 60-mm dish (stable transfection) or  $10^4$  cells per well of

96-well plate (transient transfection) and transfected one day later using the Lipofectamine 2000 (Invitrogen). For selection of stable cell lines, transfected cells were transferred to 100-mm plates and selected with appropriate antibiotics<sup>22</sup>.

### Western blotting

Cells cultured under recommended media conditions, were plated and maintained in serum-containing media without antibiotics in 14-cm plates (Nunc) until reaching 70% confluence. Cells were then treated with compounds for 6 hours, washed with cold PBS once, and lysed with M-PER Mammalian Protein Extraction Reagent (Pierce) for 30 minutes on ice. The cell lysates were centrifuged at 12,000 RPM for 15 min and the supernatants were transferred to fresh tubes and the concentrations were determined by BCA (Pierce). Equal amount of proteins were mixed with Laemmli Sample Buffer, heated at 100°C for 5 min and separated by SDS-PAGE and probed with anti-phosphoserine-51-eIF2 $\alpha$  (Phos-eIF2 $\alpha$ ), anti-total eIF2 $\alpha$ -specific antibodies (Total-eIF2 $\alpha$ ) (Biosource International, Hopkinton, MA), anti-CHOP, anti-cyclin D1 or anti-actin (Santa Cruz Biotechnology, CA) essentially as described<sup>38</sup>.

### Cell growth assay

Cells were seeded in 96-well plates and maintained for 5 days in the presence of 0.5 to 20  $\mu$ M of individual compound, and cell proliferation was measured by the sulforhodamine B (SRB) assay as described<sup>33</sup>: briefly, at the end of a 5-day treatment, cells were fixed in 10% cold trichloroacetic acid and cell numbers were estimated by measuring the remaining bound dye of sulforhodamine B after washing. The percentage of growth was calculated by using the equation:  $100 \times [(T - T_0)/(C - T_0)]$ , where T and C represent the absorbance in treated and control cultures at Day 5, and  $T_0$  at time zero, respectively. If T is less than  $T_0$ , cell death has occurred and can be calculated from  $100 \times [(T - T_0)/T_0]$ .

### Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

### Acknowledgments

This work was supported by NCI grant #1RO1CA152312 to B.H. Aktas, as well as NIEHS grant ES02710 and NIEHS Superfund Basic Research Program grant P42 ES04699 to B. D. Hammock.

### Abbreviations used

<b>HRI</b>	Heme-regulated inhibitor kinase
<b>eIF2<math>\alpha</math></b>	eukaryotic translation initiation factor 2 alpha
<b>Met-tRNA<sup>i</sup></b>	methionine transfer RNA
<b>Pi</b>	inorganic phosphate
<b>PKR</b>	protein kinase R
<b>PERK</b>	PKR-like endoplasmic reticulum kinase
<b>GCN2</b>	general control non-derepressible-2
<b>AUDA</b>	12-(3-adamantane-1-ylureido)dodecanoic acid
<b>sEH</b>	soluble epoxide hydrolase
<b>CHOP</b>	CCAAT/enhancer-binding protein homologous protein

<b>SRB</b>	sulforhodamine B
<b>RP-HPLC</b>	high performance liquid chromatography
<b>DLR</b>	dual luciferase
<b>uORF</b>	upstream open reading frame
<b>UTR</b>	untranslated region
<b>F</b>	firely
<b>R</b>	renilla
<b>ATF-4</b>	activating transcription factor 4
$\pi_x$	high lipophilicity parameters
<b>P-eIF2<math>\alpha</math></b>	phosphorylated eIF2 $\alpha$
<b>T-eIF2<math>\alpha</math></b>	total eIF2 $\alpha$
<b>TLC</b>	thin layer chromatography
<b>TFA</b>	trifluoroacetic acid
$\delta$	chemical shifts
<b>TRE</b>	transactivator response element
<b>CMV</b>	minimal human cytomegalovirus
<b>MCS</b>	multiple cloning sites


## References

1. Krishnamoorthy T, Pavitt GD, Zhang F, Dever TE, Hinnebusch AG. Tight binding of the phosphorylated alpha subunit of initiation factor 2 (eIF2alpha) to the regulatory subunits of guanine nucleotide exchange factor eIF2B is required for inhibition of translation initiation. *Mol Cell Biol.* 2001; 21:5018–5030. [PubMed: 11438658]
2. Kimball SR, Fabian JR, Pavitt GD, Hinnebusch AG, Jefferson LS. Regulation of guanine nucleotide exchange through phosphorylation of eukaryotic initiation factor eIF2alpha. Role of the alpha-and delta-subunits of eIF2b. *J Biol Chem.* 1998; 273:12841–1285. [PubMed: 9582312]
3. Harding HP, Zhang Y, Bertolotti A, Zeng H, Ron D. Perk is essential for translational regulation and cell survival during the unfolded protein response. *Mol Cell.* 2000; 5:897–904. [PubMed: 10882126]
4. Raven JF, Koromilas AE. PERK and PKR: old kinases learn new tricks. *Cell Cycle.* 2008; 7:1146–1150. [PubMed: 18418049]
5. Baltzis D, Qu LK, Papadopoulou S, Blais JD, Bell JC, Sonenberg N, Koromilas AE. Resistance to vesicular stomatitis virus infection requires a functional cross talk between the eukaryotic translation initiation factor 2alpha kinases PERK and PKR. *J Virol.* 2004; 78:12747–12761. [PubMed: 15542627]
6. Dey M, Cao C, Dar AC, Tamura T, Ozato K, Sicheri F, Dever TE. Mechanistic link between PKR dimerization, autophosphorylation, and eIF2alpha substrate recognition. *Cell.* 2005; 122:901–913. [PubMed: 16179259]
7. Takada Y, Ichikawa H, Pataer A, Swisher S, Aggarwal BB. Genetic deletion of PKR abrogates TNF-induced activation of IkappaBalpha kinase, JNK, Akt and cell proliferation but potentiates p44/p42 MAPK and p38 MAPK activation. *Oncogene.* 2007; 26:1201–1212. [PubMed: 16924232]
8. Cabanski M, Steinmuller M, Marsh LM, Surdziel E, Seeger W, Lohmeyer J. PKR regulates TLR2/TLR4-dependent signaling in murine alveolar macrophages. *Am J Respir Cell Mol Biol.* 2008; 38:26–31. [PubMed: 17690330]


9. Raven JF, Baltzis D, Wang S, Mounir Z, Papadakis AI, Gao HQ, Koromilas AE. PKR and PKR-like endoplasmic reticulum kinase induce the proteasome-dependent degradation of cyclin D1 via a mechanism requiring eukaryotic initiation factor 2alpha phosphorylation. *J Biol Chem.* 2008; 283:3097–3108. [PubMed: 18063576]
10. Shi Y, Taylor SI, Tan SL, Sonenberg N. When translation meets metabolism: multiple links to diabetes. *Endocr Rev.* 2003; 24:91–101. [PubMed: 12588811]
11. Bignon-Laubert A, Lang-Muritano M, Vaccaro T, Schoenle EJ. Loss of kinase activity in a patient with Wolcott-Rallison syndrome caused by a novel mutation in the EIF2AK3 gene. *Diabetes.* 2002; 51:2301–2305. [PubMed: 12086964]
12. Chen JJ. Regulation of protein synthesis by the heme-regulated eIF2alpha kinase: relevance to anemias. *Blood.* 2007; 109:2693–2699. [PubMed: 17110456]
13. Chen, JJ. Heme-regulated eIF2 $\alpha$  Kinase. In: Sonenberg, N.; Hershey, JWB.; Mathews, MB., editors. *Translational control of gene expression.* Cold spring harbor laboratory press; New York: 2000. p. 529-546.
14. Han AP, Fleming MD, Chen JJ. Heme-regulated eIF2alpha kinase modifies the phenotypic severity of murine models of erythropoietic protoporphyria and beta-thalassemia. *J Clin Invest.* 2005; 115:1562–1570. [PubMed: 15931390]
15. Couturier J, Page G, Morel M, Gontier C, Claude J, Pontcharraud R, Fauconneau B, Paccalin M. Inhibition of double-stranded RNA-dependent protein kinase strongly decreases cytokine production and release in peripheral blood mononuclear cells from patients with Alzheimer's disease. *J Alzheimers Dis.* 2010; 21:1217–1231. [PubMed: 21504114]
16. Donze O, Jagus R, Koromilas AE, Hershey JW, Sonenberg N. Abrogation of translation initiation factor eIF-2 phosphorylation causes malignant transformation of NIH 3T3 cells. *Embo J.* 1995; 14:3828–3834. [PubMed: 7641700]
17. Berns A. A tRNA with oncogenic capacity. *Cell.* 2008; 133:29–30. [PubMed: 18394985]
18. Marshall L, Kenneth NS, White RJ. Elevated tRNA(iMet) synthesis can drive cell proliferation and oncogenic transformation. *Cell.* 2008; 133:78–89. [PubMed: 18394991]
19. Dever TE, Yang W, Astrom S, Bystrom AS, Hinnebusch AG. Modulation of tRNA(iMet), eIF-2, and eIF-2B expression shows that GCN4 translation is inversely coupled to the level of eIF-2.GTP. Met-tRNA(iMet) ternary complexes. *Mol Cell Biol.* 1995; 15:6351–6363. [PubMed: 7565788]
20. Aktas H, Fluckiger R, Acosta JA, Savage JM, Palakurthi SS, Halperin JA. Depletion of intracellular Ca<sup>2+</sup> stores, phosphorylation of eIF2alpha, and sustained inhibition of translation initiation mediate the anticancer effects of clotrimazole. *Proc Natl Acad Sci U S A.* 1998; 95:8280–8285. [PubMed: 9653178]
21. Aktas BH, Qiao Y, Ozdelen E, Schubert R, Sevinc S, Harbinski F, Grubissich L, Singer S, Halperin JA. Small-Molecule targeting of translation initiation for cancer therapy. *Oncotarget.* 2013; 4:1606–1617. [PubMed: 24091475]
22. Bai H, Chen T, Ming J, Sun H, Cao P, Fusco DN, Chung RT, Chorev M, Jin Q, Aktas BH. Dual activators of protein kinase R (PKR) and protein kinase R-like kinase PERK identify common and divergent catalytic targets. *Chembiochem.* 2013; 14:1255–1262. [PubMed: 23784735]
23. Denoyelle S, Chen T, Yang H, Chen L, Zhang Y, Halperin JA, Aktas BH, Chorev M. Synthesis and SAR study of novel 3,3-diphenyl-1,3-dihydroindol-2-one derivatives as potent eIF2.GTP. Met-tRNA ternary complex inhibitors. *Eur J Med Chem.* 2013; 69C:537–553. [PubMed: 24095748]
24. Chen L, Aktas BH, Wang Y, He X, Sahoo R, Zhang N, Denoyelle S, Kabha E, Yang H, Freedman RY, Supko JG, Chorev M, Wagner G, Halperin JA. Tumor suppression by small molecule inhibitors of translation initiation. *Oncotarget.* 2012; 3:869–881. [PubMed: 22935625]
25. Chen T, Ozel D, Qiao Y, Harbinski F, Chen L, Denoyelle S, He X, Zvereva N, Supko JG, Chorev M, Halperin JA, Aktas BH. Chemical genetics identify eIF2alpha kinase heme-regulated inhibitor as an anticancer target. *Nat Chem Biol.* 2011; 7:610–616. [PubMed: 21765405]
26. Denoyelle S, Chen T, Chen L, Wang Y, Klosi E, Halperin JA, Aktas BH, Chorev M. In vitro inhibition of translation initiation by N,N'-diarylureas--potential anti-cancer agents. *Bioorg Med Chem Lett.* 2012; 22:402–409. [PubMed: 22153346]




27. Morisseau C, Hammock BD. Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health. *Annu Rev Pharmacol Toxicol.* 2013; 53:37–58. [PubMed: 23020295]
28. Shen HC, Hammock BD. Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications. *J Med Chem.* 2012; 55:1789–1808. [PubMed: 22168898]
29. Scherman MS, North EJ, Jones V, Hess TN, Grzegorzewicz AE, Kasagami T, Kim IH, Merzlikin O, Lenaerts AJ, Lee RE, Jackson M, Morisseau C, McNeil MR. Screening a library of 1600 adamantyl ureas for anti-*Mycobacterium tuberculosis* activity in vitro and for better physical chemical properties for bioavailability. *Bioorg Med Chem.* 2012; 20:3255–3262. [PubMed: 22522007]
30. Hwang SH, Morisseau C, Do Z, Hammock BD. Solid-phase combinatorial approach for the optimization of soluble epoxide hydrolase inhibitors. *Bioorg Med Chem Lett.* 2006; 16:5773–5777. [PubMed: 16949285]
31. Madar, DJ.; Djuric, SW.; Michmerhuizen, MJ.; Kopecka, HA.; Li, X.; Longenecker, KL.; Pei, Z.; Pireh, D.; Sham, HL.; Stewart, KD.; Szczepankiewicz, BG.; Wiedeman, PE.; Yong, H. Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV). US Patent. 20050215784 A1. 2005.
32. Ziegeler G, Ming J, Koseki JC, Sevinc S, Chen T, Ergun S, Qin X, Aktas BH. Embryonic lethal abnormal vision-like HuR-dependent mRNA stability regulates post-transcriptional expression of cyclin-dependent kinase inhibitor p27Kip1. *J Biol Chem.* 2010; 285:15408–15419. [PubMed: 20332085]
33. Palakurthi SS, Fluckiger R, Aktas H, Changolkar AK, Shahsafaei A, Harneit S, Kilic E, Halperin JA. Inhibition of translation initiation mediates the anticancer effect of the n-3 polyunsaturated fatty acid eicosapentaenoic acid. *Cancer Res.* 2000; 60:2919–2925. [PubMed: 10850438]
34. Sheppard CW. The Effect of Fluorine Substitution on the Electronic Properties of Alkoxy, Alkylthio and Alkylsulfonyl Groups. *J Am Chem Soc.* 1963; 85:1314–1318.
35. AH. The Element Displacement Principle: A new Guide in p-Block Element Chemistry. Vol. 28. Academic Press Inc; Orlando, FL: 1884. p. 167-202.
36. O'Hagan D. Understanding organofluorine chemistry. An introduction to the C–F bond. *Chem Soc Rev.* 37:308–319. [PubMed: 18197347]
37. Hwang SH, Tsai HJ, Liu JY, Morisseau C, Hammock BD. Orally bioavailable potent soluble epoxide hydrolase inhibitors. *J Med Chem.* 2007; 50:3825–3840. [PubMed: 17616115]
38. Aktas H, Cai H, Cooper GM. Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27KIP1. *Mol Cell Biol.* 1997; 17:3850–3857. [PubMed: 9199319]



**Figure 1.** Activity of *N*-phenyl-*N'*-(4-phenoxy)cyclohexylureas **I** in the surrogate eIF2 $\alpha$  phosphorylation assay. Activity of compounds was measured by DLR assay, the F/R ratio normalized to vehicle treated cells, and expressed as a function of the compounds' concentration. *N*-phenyl,*N'*-cyclohexylaryureas were sorted into three groups based on the nature of R<sub>1</sub> on the *N*-phenyl substituent: (Panel A) halogen substituent; (Panel B) electron donating groups; and (Panel C) mostly electron withdrawing groups. The experiment was conducted in triplicate and each experiment was independently performed three times; data are shown as Mean $\pm$ S.E.M.




**Figure 2.** *N*-phenyl,*N'*-(4-phenoxy)cyclohexylureas cause phosphorylation of eIF2 $\alpha$ . CRL-2813 human melanoma cells were incubated with selected *N*-phenyl,*N'*-(4-phenoxy)cyclohexylureas and phosphorylated (P-eIF2 $\alpha$ ) and total eIF2 $\alpha$  (T-eIF2 $\alpha$ ) were analyzed by Western blot using pS51-eIF2 $\alpha$ -specific rabbit monoclonal antibodies or total eIF2 $\alpha$ -specific mouse monoclonal antibodies, respectively. The experiment was independently performed three times.



**Figure 3. Effect of *N*-phenyl,*N'*-(4-phenoxy)cyclohexylureas on protein and mRNA expressions of CHOP and cyclin D1**


(A) Human CRL-2813 melanoma cells were incubated with 10  $\mu$ M of each compound for 6 hours. Expression of CHOP and cyclin D1 proteins was determined by Western blot analysis. A representative gel from three independent experiments is shown. (B and C) CRL-2813 cells were incubated with 7.5 or 15  $\mu$ M of each compound for 6 hours. Expression of CHOP and (B) cyclin D1 (C) mRNAs was determined by real time PCR analysis. Each experiment was carried out in triplicate, data shown are mean of three independent experiments, and error bars are  $\pm$ S.E.M.



**Figure 4. *N*-phenyl,*N'*-(4-phenoxy)cyclohexylureas (I) reduce the abundance of the ternary complex by activating HRI**


Stably transfected CRL-2813-pBISA-DL(ATF-4) cells were transiently transfected with either non-targeting siRNA, or siRNA targeting HRI for 48 hours. Cells were treated with *N*-phenyl,*N'*-phenoxy cyclohexylurea compounds or DMSO for 10 hours and the normalized F/R ratio was determined by DLR assay. The experiment was conducted in triplicate and each experiment was independently performed three times; Data are shown as Mean±S.E.M.






**Figure 5. HRI mediates inhibition of cancer cell proliferation by *N*-phenyl,*N'*-(4-phenoxy)cyclohexylureas**


(A) CRL-2813 human melanoma cancer cells and (B) MCF-7 human breast cancer cells were transfected with HRI targeted or non-targeted siRNA, treated with the indicated concentrations of **I-6p** and cell proliferation was measured by SRB assay. (C and D) Calculated IC<sub>50</sub> for all four compounds tested in CRL-2813 human melanoma cancer cells (C) and MCF-7 human breast cancer cells (D) transfected with non-targeting siRNA control or HRI targeting siRNA. The experiment was conducted in triplicate and each experiment was independently performed three times. Data are shown as Mean ± S.E.M, \*NTC = non-targeting siRNA control.



**Figure 6.** Dose-response studies of the phenoxy substituted 1-(4-phenoxy-cyclohexyl)-3-(3-(trifluoromethyl)phenyl)ureas, I-14-20, in the surrogate eIF2 $\alpha$  phosphorylation assay. Activity of compounds was measured by determining the F/R normalized to vehicle treated cells, and expressed as a function of the concentration. The experiment was conducted in triplicate and each experiment was independently performed three times; Data are shown as Mean $\pm$ S.E.M.




**Figure 7. Activity of compounds in which the phenoxy moiety is either missing or relocated to another position on the cyclohexyl in surrogate eIF2 $\alpha$  phosphorylation assays**  
 Activity of compounds was measured by DLR assay and F/R ratio was normalized to vehicle treated cells, and expressed as a function of the concentration. The experiment was conducted in triplicate and each experiment was independently performed three times; Data are shown as Mean $\pm$ S.E.M.



**Figure 8. Newly synthesized 1-(4-phenoxy-cyclohexyl)-3-(3-(trifluoromethyl)phenyl)ureas display higher HRI dependence for inhibition of cell proliferation**


CRL-2813 human melanoma cancer cells were transfected with HRI targeting or non-targeting siRNA, treated with the indicated concentrations of (A) **I-14**, (B) **I-15**, (C) **I-17** and (D) **I-18** and cell proliferation was measured by SRB assay. Calculated IC<sub>50</sub> values for library compound **I-5m** and **I-14**, **I-15**, **I-17**, **I-18**, and **I-20** in CRL-2813 human melanoma cancer cells transfected with non-targeting siRNA or HRI-targeting siRNA are shown in (E). The experiment was conducted in triplicate and each experiment was independently performed three times. Data are shown as Mean ± S.E.M. \*NTC = non-targeting control.

**Scheme 1.**

Synthesis of *trans*- and *cis*-*N*-phenyl-*N'*-(4-phenoxy)cyclohexylureas.<sup>#</sup>

<sup>#</sup>**Reagents and conditions:** i) NaH, DMF, reflux, 2h. ii) Triethylamine, DMF or DCM/DMSO, RT, 16 h. iii) (1) 4-Fluorophenol, PPh<sub>3</sub>, *p*-nitrobenzoic acid, DIAD, THF, RT, 12 h; (2) 35% aqueous hydrazine, CH<sub>2</sub>Cl<sub>2</sub>, MeOH, RT, 1 day. iv) LiOH, CH<sub>3</sub>CN/H<sub>2</sub>O, 24h.



**Scheme 2.**

Synthesis of substituted cyclohexylamines and their corresponding ureas<sup>#</sup>.

<sup>#</sup>**Reagents and conditions:** i) Boc<sub>2</sub>O, MeOH, RT, 16 hrs. ii) NaH, 4-fluorobenzyl bromide, THF, RT, 16 hrs. iii) 4-substituted fluorobenzene, NaH, DMF, reflux, 2h. iv) TFA/DCM, 2 hrs, 16 hrs. v) 3-(trifluoromethyl)phenyl isocyanate, triethylamine, DMF, RT, 16 hrs

Table 1

Activity of *N*-phenyl-*N'*-(4-(4-fluorophenoxy)cyclohexyl)ureas, **I**, in the ternary complex and cell proliferation assay.

Compound	R <sub>1</sub>	CLogP	IC <sub>50</sub> (μM)	E <sub>max</sub> (F/R)	C <sub>3X</sub> <sup>c</sup> (μM)
<b>I-1o</b>	<i>o</i> -F	4.15	17.5±1.1	2.10	N.A.
<b>I-1m</b>	<i>m</i> -F	4.60	8.3±0.9	6.54	13.5
<b>I-1p</b>	<i>p</i> -F	4.60	20±2.1	0.98	N.A.
<b>I-2o</b>	<i>o</i> -Cl	4.61	9.1±1.0	5.37	18.5
<b>I-2m</b>	<i>m</i> -Cl	5.17	5.9±0.6	8.76	6.4
<b>I-2p</b>	<i>p</i> -Cl	5.17	>20	1.65	N.A.
<b>I-3o</b>	<i>o</i> -Br	4.76	7.7±0.1	5.23	16.4
<b>I-3m</b>	<i>m</i> -Br	5.32	6.2±0.3	9.52	5.7
<b>I-3p</b>	<i>p</i> -Br	5.32	>20	1.29	N.A.
<b>I-4o</b>	<i>o</i> -I	4.92	>20	3.25	18.5
<b>I-4m</b>	<i>m</i> -I	5.58	5.2±0.2	10.32	5.6
<b>I-4p</b>	<i>p</i> -I	5.58	10.2±1.5	3.77	6.3
<b>I-5o</b>	<i>o</i> -CF <sub>3</sub>	4.69	>20	1.56	N.A.
<b>I-5m<sup>d</sup></b>	<i>m</i> -CF <sub>3</sub>	5.57	2.6±0.3	11.84	4.5
<b>I-5p</b>	<i>p</i> -CF <sub>3</sub>	5.57	2.8±0.1	13.99	1.6
<b>I-6o</b>	<i>o</i> -CF <sub>3</sub> O	5.36	>20	1.41	N.A.
<b>I-6p</b>	<i>p</i> -CF <sub>3</sub> O	3.81	2.7±0.1	15.32	0.7
<b>I-13</b>	H	4.15	20±2.0	1.65	N.A.
<b>I-7o</b>	<i>o</i> -Me	4.09	>20	0.98	N.A.
<b>I-7m</b>	<i>m</i> -Me	4.65	14.4±0.5	4.73	24.1
<b>I-7p</b>	<i>p</i> -Me	4.65	>20	1.05	N.A.
<b>I-8o</b>	<i>o</i> -MeO	4.26	>20	1.51	N.A.
<b>I-8m</b>	<i>m</i> -MeO	4.26	14±1.3	3.81	26.0
<b>I-8p</b>	<i>p</i> -MeO	4.26	>20	0.83	N.A.
<b>I-9o</b>	<i>o</i> -NO <sub>2</sub>	4.54	3.5±0.3	2.23	N.A.
<b>I-9m</b>	<i>m</i> -NO <sub>2</sub>	4.54	6.7±0.7	7.47	11.4
<b>I-9p</b>	<i>p</i> -NO <sub>2</sub>	4.54	2.3±0.1	9.00	6.7

Compound	R <sub>1</sub>	CLogP	IC <sub>50</sub> (μM)	E <sub>max</sub> (F/R)	C <sub>3X</sub> <sup>c</sup> (μM)
<b>I-10o</b>	<i>o</i> -MeS	4.71	>20	0.92	N.A.
<b>I-10m</b>	<i>m</i> -MeS	4.71	11.1±1.1	6.67	12.2
<b>I-10p</b>	<i>p</i> -MeS	4.71	>20	1.07	N.A.
<b>I-11o<sup>a,b</sup></b>	<i>o</i> -CO <sub>2</sub> Me	4.67	14.5±1.6	3.79	26.2
<b>I-11m</b>	<i>m</i> -CO <sub>2</sub> Me	4.67	9.2±0.8	6.83	17.1
<b>I-11p</b>	<i>p</i> -CO <sub>2</sub> Me	4.67	11.6±1.2	3.97	12.8
<b>I-12o<sup>a,b</sup></b>	<i>o</i> -CO <sub>2</sub> H	4.87	>20	1.20	N.A.
<b>I-12m</b>	<i>m</i> -CO <sub>2</sub> H	4.24	>20	0.88	N.A.
<b>I-12p</b>	<i>p</i> -CO <sub>2</sub> H	4.24	11.6±1.8	3.49	21.2

<sup>a</sup>Reported as a *cis*-isomer.



<sup>b</sup>Compounds synthesized as described in Scheme 1, all other compounds were part of UC-Davis Library.

<sup>c</sup>C<sub>3X</sub>: Calculated concentration at which F/R=3.

Table 2

Activity of the phenoxy substituted 1-(4-phenoxy cyclohexyl)-3-(3-(trifluoromethyl)phenyl)ureas, **I-14-20**, in the surrogate eIF2 $\alpha$  phosphorylation and cell proliferation assays.






Compound	Structure	CLogP	IC <sub>50</sub> ( $\mu$ M)	E <sub>max</sub> (F/R)	C <sub>3X</sub> <sup>a</sup> ( $\mu$ M)
<b>I-5m</b>		5.57	2.6 $\pm$ 0.6	11.84	4.5
<b>I-14</b>		5.37	2.45 $\pm$ 0.9	7.98	3.2
<b>I-15</b>		5.57	2.4 $\pm$ 0.6	7.23	2.6
<b>I-16</b>		6.14	2.0 $\pm$ 0.1	6.73	1.6
<b>I-17</b>		6.48	0.69 $\pm$ 0.1	15.42	1.5
<b>I-18</b>		6.41	0.46 $\pm$ 0.1	25.12	0.3


Compound	Structure	CLogP	IC <sub>50</sub> (μM)	E <sub>max</sub> (F/R)	C <sub>3X</sub> <sup>a</sup> (μM)
<b>I-19</b>		6.41	1.4±0.3	15.74	1.2
<b>I-20</b>		6.41	1.3±0.1	26.00	1.1

<sup>a</sup>C<sub>3X</sub>: Calculated concentration at which F/R=3.

Table 3

SAR study to identify the minimum pharmacophore.

Compound	Structure	CLogP	IC <sub>50</sub> (μM)	E <sub>max</sub> (F/R)	C <sub>50</sub> <sup>h</sup> (μM)
I-18		6.41	0.46±0.1	25.12	0.3
III-1		4.54	13.2±2.3	1.87	N.A.
III-2		2.46	>20	0.89	N.A.
III-3		5.16	2.65±0.8	9.58	4.4
III-4		6.98	3.1±1.1	5.89	1.7

Compound	Structure	<i>CL</i> <sub>50</sub> P	<i>IC</i> <sub>50</sub> (μM)	<i>E</i> <sub>max</sub> (F/R)	<i>C</i> <sub>3X</sub> <sup>a</sup> (μM)
III-5		6.85	3.8±1.2	4.52	2.7

<sup>a</sup> *C*<sub>3X</sub>: Calculated concentration at which F/R=3.



**Table 4**Selective inhibition of cancer cell proliferation by *N*-aryl,*N'*-cyclohexylarylureas.

IC <sub>50</sub> of compounds (μM)				
	<b>I-6p</b>	<b>I-17</b>	<b>I-18</b>	<b>I-20</b>
NIH/3T3	13.6±0.8	3.4±0.2	3.4±0.1	3.3±0.2
CRL-2813	2.7±0.1	0.69±0.1	0.46±0.1	1.30±0.1

Compounds **I-6p**, **I-17**, **I-18** and **I-20** were tested in NIH/3T3 fibroblast and CRL-2813 melanoma cancer cells in cell proliferation assay. The experiment was conducted in triplicate and each experiment was independently performed three times. Data are shown as Mean IC<sub>50</sub>±S.E.M.